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CHAPfER I
INTRODUCTION

A stressful stimulus can be defined as a threat (real or perceived) to an
organism's survival, integrity, or reproductive success. The adaptive biological
reactions to such a stimulus have been termed the stress response. The animal's full
attention and integrated action may be required in order to achieve survival and to
eliminate the threatening stimulus. To this end, the stress response involves changes
in several physiological and behavioral parameters. For example, activation of the
endocrine and the autonomic nervous systems serves to increase the probability of
survival of the organism and to terminate the stress response once the source of the
stress has been eliminated.
In mammals, the hypothalamo-pituitary-adrenal (HPA) axis is an important

component of an organism's adaptive response to stress. Neurons involved in the
initiation of this response synthesize corticotropin-releasing hormone (CRH). These
neurons are mainly located in the parvocellular region of the paraventricular nucleus
(PVN) of the hypothalamus. These neurons project to the median eminence where

they secrete CRH into the hypophysial portal vasculature. CRH stimulates
corticotrophs of the anterior pituitary to secrete adrenocorticotropic hormone (ACTH)
into the peripheral circulation. ACTH then induces the secretion of corticosterone
(CORT) from the adrenal cortex. During stressful events, corticosteroids act to
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preserve the integrity of the organism by altering several physiological parameters.
For example, CORT increases glucose mobilization in order to provide the animal
with the necessary energy to contend with the stressor.
Gonadal hormones are also known to influence HPA activity. A sex
difference in basal CORT titers and . in the CORT response to stress has been
demonstrated (Kitay, 1961). Females have higher basal CORT levels and enhanced
CORT responses to stress compared to males. The greater secretion in females is
believed to be the result of estrogen acting to enhance HPA activity (Kitay, 1963;
Viau and Meaney, 1991a; Burgess and Handa, 1992). Conversely, in males
androgens may inhibit HPA activity (Critchlow et al., 1963; Gaskin and Kitay, 1971;
Handa et al., 1994; Viau and Meaney, 199lb). Previous studies have shown that
prepuberal gonadectomy of the male rat and hamster leads to enhanced levels of
CORT which correlate with increases in ACTH bioactivity (Critchlow et al., 1963;
Gaskin and Kitay, 1971). In gonadectomized male rats, the CORT and ACTH
responses to foot shock or open field stressors are enhanced compared to intact
animals (Handa et al., 1994). Furthermore, treatment of gonadectomized rats with
testosterone or the non-aromatizable androgen, dihydrotestosterone (DHT), normalizes
post-stress plasma CORT and ACTH levels. These data provide further evidence that
the sex difference in HPA activity arises as a result of the circulating gonadal steroid
environment.
Several possible mechanisms could explain androgen's inhibition of HPA
activity. Androgens could be inhibiting synthesis and/or secretion of hypothalamic
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CRH (or other corticotropin-releasing factors such as arginine vasopressin, AVP).
Alternatively, androgens may influence the negative feedback response of the HPA

axis. However, this is not supported by evidence that gonadectomy of male rats does
not alter the concentration or affinity of type I or type II CORT receptors in the
hippocampus or hypothalamus (Handa et al., 1994). Furthermore, anterior pituitary
responsiveness to CRH is not altered following gonadectomy of male rats (Handa et

al., 1994). The possibility remains that androgens could be influencing hypothalamic
CRH synthesis, storage, or secretion.
It is important to characterize the effect(s) of gonadal hormones on the stress

response. Dysfunction of the stress response is believed to lead to adjustment
disorders such as depression and panic disorder. These disorders occur much more
often in females than in males (Weissman and Klerman, 1977; Katschnig and
Amering, 1990). While it is clear that estrogen may play an important role in
predisposing a female to such disorders, it is equally as important to determine what
role androgens may play in protecting a male from dysfunction of the stress response.
Thus, this dissertation tested the hypothesis that in the male rat, circulating

androaens modulate the neuronal circuitry responsible for mediatin&
neuroendocrine and behavioral responses to stressful stimuli. This hypothesis was
tested in two parts. First, the effect of circulating gonadal androgens on the HPA
axis was examined, and secondly, the effect of circulating androgens on other
neuroendocrine and behavioral responses to stress was evaluated.
Four experiments were conducted to test this general hypothesis. The. first
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experiment tested the hypothesis that androgens affect the HPA axis by reducing
hypothalamic CRH levels. Thus, the first experiment examined the effect of
gonadectomy and the non-aromatizable androgen, DHT, on hypothalamic CRH
content and CRH-immunoreactive (IR) cell numbers within the PVN of male rats.
The second experiment was performed to test the hypothesis that the influence of
androgens on CRH content and CRH immunoreactivity in the hypothalamus are a
consequence of changes in CRH gene expression as determined by measuring steady
state levels of CRH mRNA. CRH mRNA levels in the PVN of intact,
gonadectomized, and gonadectomized, DHT-treated animals were evaluated using in

situ hybridization histochemistry (ISHH). The third experiment tested the hypothesis
that androgens regulate CRH by acting directly within CRH containing cells of the
PVN. The regulation of cellular processes by androgens requires the presence of the
androgen receptor (AR) which acts as a ligand-responsive transcription factor. In
order for androgens to directly regulate hypothalamic CRH, AR must be expressed
within CRH containing cells of the PVN. Therefore, this experiment tested for the
presence of AR immunoreactivity within CRH neurons in the PVN of male rats. The
purpose of the final study was to test the hypothesis that circulating androgens
influence neuroendocrine, autonomic, and behavioral responses to a psychological
stressor. The effects of conditioned stress were examined in male rats that were
intact, gonadectomized, or gonadectomized and treated with DHT. The effects of
gonadal androgens on the stress-induced increases in plasma corticosterone, ACTH,
prolactin, renin concentration, and renin activity were examined. In addition, this
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experiment examined the influence of androgens on the stress-induced changes in
defecation and several behavioral parameters.

CHAPTERil
REVIEW OF RELATED LITERATURE

The "Stress Response"
The terms "stress" and "homeostasis" were coined to describe very basic yet
significant concepts of interaction between an organism and its environment. The
concept of "homeostasis" was described by Cannon (1939) as a closed system of
processes which defend the steady state against environmental stimuli that tend to
disturb the balance. Selye (1950) observed that the body reacts to any nonspecific
noxious agent or tissue damage with the same syndrome: hypertrophy of the adrenal,
atrophy of the thymus, and development of gastric ulcers. He thus introduced the
word "stress" to describe the state of the organism during the response to the noxious
or threatening stimuli. More recently, the term "stress" has been used to refer to any
perturbations of homeostasis and may be physiological or psychological in nature.
In mammals, most physiological systems are affected in some way by stressful
stimuli. The endocrine system, the autonomic system, and the immune system are all
sensitive to such environmental changes. Stressful stimuli elicit increases in plasma
levels of several hormones including corticosterone, prolactin, and oxytocin.
Autonomic outputs evoke changes in the cardiovascular, respiratory, and other
visceral systems. Changes in immune function include a suppression of T lymphocyte

6

7
mitogen responsiveness (Cunnick et al., 1991). All of these changes serve to
preserve the integrity of the organism by increasing the readiness and execution of
behaviors. This will ultimately enhance the probability of survival of the organism

and eliminate the source of the stress. In addition, these physiological reactions
ensure the termination of the stress response once the source of the stress has been
eliminated. Thus, the "stress response" is an integral part of an adaptive biological
system.

The Hypothalamo-Pituitary-Adrenal Axis
The hypothalamo-pituitary-adrenal (HPA) axis is a major component of the
stress response (see Figure 1). Parvocellular neurosecretory neurons located in the
paraventricular nucleus of the hypothalamus (PVN) synthesize a neuropeptide
hormone, corticotropin-releasing hormone (CRH). These neurons project to the
median eminence and terminate around the primary capillaries of the hypophysial
portal circulation. The hypothalamus secretes CRH (and other corticotropin-releasing
factors) into the hypophysial portal vasculature (Plotsky and Vale, 1984).
Corticotropin-releasing hormone is the primary stimulus causing corticotrophs of the
anterior pituitary to synthesize and secrete adrenocorticotropic hormone (ACTH) into
the peripheral circulation (Rivier et al., 1982). Subsequently, ACTH stimulates the
cells of the zona fasciculata to synthesize and secrete glucocorticoids (predominantly
corticosterone, CORT, in rats and cortisol in humans; Makara, 1985; Baxter 1986).
The activity of the HPA axis is influenced by both a circadian pacemaker and
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HIPPOCAMPUS

+
HYPOTHALAMUS
(PARA VENTRICULAR NUCLEUS)

CRH

+
ANTERIOR PITUITARY
ACTH

+
ADRENAL CORTEX

~CORTilSTERONE
PHYSIOLOGICAL EFFECTS

Figure 1. The hypothalamo-pituitary-adrenal (HPA) axis. In response to stress,
corticotropin-releasing hormone (CRH) is secreted from the hypothalamus. CRH
stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) which
subsequently stimulates the release of corticosterone (CORT) from the adrenal cortex.
In addition to its systemic effects, CORT feeds back on the hippocampus,
hypothalamus, and pituitary to bring CRH, ACTH, and CORT secretion back to
baseline levels.
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environmental stimuli. Plasma CORT levels exhibit a diurnal rhythm with peak
circulating CORT titers at the onset of the animal's active period (Dallman et al.,
1987). In addition to the circadian fluctuations, HPA activity increases rapidly in
response to stressful stimuli. The HPA response to environmental perturbation
corresponds with the circadian rhythm of the axis in that the response is greatest in
the morning when plasma CORT titers are at their circadial nadir (Bradbury et al.,
1991). During stress, corticosteroids feedback on the hippocampus, hypothalamus,
and pituitary to bring CRH, ACTH, and adrenal steroid secretion back to basal levels
(Kim and Kim, 1961; Jingami et al., 1985; Sapolsky et al.,1990).
The role of circulating CORT during stress is believed to be protective in
nature. Corticosteroids dampen physiological responses involving immunity,
inflammation, water resorption, and glucose utiliz.ation (for rev. see Munck et al.,
1984; Axelrod and Reisine, 1984). The exposure to a noxious or threatening stimulus
induces defense reactions such as inflammation following tissue damage. These
responses may become detrimental if they are not terminated once the threatening
stimulus has disappeared. It has been suggested that during stress, glucocorticoids
inhibit the synthesis and release of several intracellular mediators of these defense
reactions (Munck et al., 1984). Thus, corticosteroids act to prevent an overreaction
to stress. In addition, glucocorticoids increase the synthesis of enzymes involved in
gluconeogenesis in hepatocytes (Weber et al., 1955; Weber et al., 1964). This serves
to increase the available energy such that the organism is better equipped to contend
with or escape from a threatening stimulus.
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In addition to CORT's effects on peripheral physiology, CORT also has

profound effects upon the central nervous system. Adrenalectomy and corticosterone
treatment have been shown to alter catecholaminergic, monoaminergic, peptidergic,

and amino acid neurotransmitter systems (for rev. see McEwen et al., 1986). For
example, corticosterone treatment increases dopamine turnover and release (Versteeg
et al., 1983; Imperato et al., 1989) and decreases hippocampal norepinepherine-

stimulated cAMP production (Harrelson and McEwen, 1987). The effects of CORT
on these neurotransmitter systems may be involved in the regulation of mood,
perception, attention and learning (McEwen et al., 1986).
Although glucocorticoids can serve a protective function, chronically high
levels of circulating CORT can be detrimental. Chronically elevated plasma CORT
can lead to steroid diabetes, hypertension, osteoporosis, immunosuppression, neuronal
loss, impaired reproductive function, and disturbances in mood and cognitive function
(Seyle and Tuchweber, 1976; Munck et al., 1984; Sapolsky et al., 1985; McEwen et
al., 1986). Since these are all symptoms of aging, it has been suggested that
chronically elevated CORT titers may be related to the aging process and age-related
neuropathology (Landfield et al., 1978; Landfield et al., 1981; Sapolsky et al., 1986).

Corticotropin-Releasing Hormone (CRH) and Factors (CRFs)
Over a decade ago, Vale and colleagues (1981) sequenced and characterized
CRH, the 41-amino acid peptide that serves as the major physiological stimulus for
adenohypophysial ACTH secretion. The evidence indicating that CRH induces
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adenOhYJ>OPhysial CRH secretion is extensive. CRH has been shown to stimulate the

release of ACTH both in vitro (Vale et al., 1983a) and in vivo (Rivier et al., 1982).
Stimulation of ACTH release by endogenous CRH is attenuated by anti-CRH
antibodies (Rivier et al., 1984a; Van Oers et al., 1989). Also, administration of
CRH antisera nearly abolishes the pituitary and adrenal responses to a variety of
stressors (Rivier and Vale, 1983; Ono et al., 1985). In addition to increasing
secretion of ACTH, CRH increases the synthesis and release of other
adenohypophysial products of the ACTH precursor peptide, proopiomelanocortin
(POMC; Rivier and Plotsky, 1986; Vale et al., 1983b) and the level of POMC
mRNA (Bruhn et al., 1984; Dallman et al., 1985) in corticotroph cells of the anterior
pituitary.
Several other hypothalamic substances including arginine vasopressin, (AVP;
Gillies et al., 1982; Rivier et al., 1984b; Giguere and Labrie, 1982; Rivier and Vale
1983; Antoni et al., 1983; Vale et al., 1983a), oxytocin (Antoni et al., 1983; Vale et
al., 1983a), and catecholamines (Vale and Rivier, 1977) synergize with CRH in its

effects on adenohypophysial ACTH release. These substances have been proposed to
be "CRFs". Interactions between.these CRFs appear to be physiologically important
since the secretion of each CRF is stimulus specific (Plotsky et al., 1985a; Plotsky et
al., 1985b). For example, during insulin-induced hypoglycemia increases in plasma

ACTH levels have been shown to accompany increases in AVP, but not CRH or
catecholamines, in the portal blood (Plotsky et al., 1985a).
Several laboratories have demonstrated that neurohypophysial AVP potentiates
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the effect of CRH on pituitary corticotrophs in both rats (Giguere and Labrie, 1982;
Rivier and Vale, 1985a; Graf et al., 1985) and humans (Orth et al., 1985). AVP acts
throUgh its receptor subtype, Vl, (Rivier et al., 1984b) to potentiate CRH-stimulated

cAMP accumulation (Giguere and Labrie, 1982). However, it is currently thought
that CRH is the only hypothalamic factor capable of inducing POMC gene expression

(Levin et al., 1989). A VP may potentiate CRH action by increasing CRH receptors
on the corticotroph cell surface (Madsen et al. , 1991; Jia et al. , 1991). AVP may
accomplish this through its action on a functionally distinct population of corticotrophs
which does not contain CRH receptors (Schwartz and Vale, 1988; Jia et al., 1991).
In the rat, oxytocin amplifies the ACTH response to CRH much in the same
way as AVP does (Antoni et al., 1983; Vale et al., 1983a). The effects of oxytocin
and AVP on ACTH secretion are not additive (Gibbs et al., 1984). It is therefore
likely that these neuropeptides act via the same intracellular pathways. Although
oxytocin has not been shown to influence plasma ACTH levels in humans (Lewis and
Sherman, 1985), oxytocin appears to be an important CRF in the rat. The levels of
oxytocin in the hypophysial portal blood of the rat are 50-100 times higher than the
concentration in peripheral blood (Gibbs, 1985; Horn et al., 1985). The source of
this hypophysial portal oxytocin is the axons of magnocellular neurons of the
supraoptic and accessory nuclei which are passing through the median eminence
(Antoni et al., 1986).
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The CRH Gene
The gene encoding the CRH prohormone has been cloned and sequenced in
several species (Furutani et al., 1983; Shibahara et al., 1983; Jingami et al., 1985;
Thompson et al., 1987). The genes encoding rat and human CRH precursors are
highly homologous and are comprised of two exons separated by an intervening intron
(see Figure 2; Jingami et al., 1985; Thompson et al., 1987). The nucleotide
sequence encoding the entire CRH prohormone is located on the second exon while
the first exon encodes most of the 5 '-untranslated regions of the mRNA. Comparison
of the human and rat gene reveals a high degree of homology not only in the peptide
encoding region, but also in the 5'-flanking sequence. The 5'-flanking region is
likely to contain DNA sequence elements responsible for tissue specific expression as
well as second messenger and steroid regulation of gene expression. For example, a
cAMP-responsive element has been localized to a 59-base pair region located between
238 and 180 base pairs 5' to the CRH cap site (Seasholtz et al., 1988).
Induction of immediate early genes such as c-fos may be involved in CRH
gene expression. Induction of c-Fos immunoreactivity has been observed in CRHimmunoreactive (IR) parvocellular neurons of the PVN following various stressors
(Ceccatelli et al., 1989a) as well as following adrenalectomy (Jacobson et al., 1990).
Recently, a temporal correlation was reported in which the enhanced expression of
CRH mRNA in the PVN following immobilization stress was preceded by the
induction of c-fos mRNA (lmaki et al., 1992). However, this is contradicted by a
study demonstrating that CRH heterogeneous nuclear RNA and c-fos mRNA rise
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intron

CRH

Rat CRH Gene

CRH

RatCRHmRNA

jcRHj

Rat CRH Protein Precursor

Figure 2. Structural organization of the rat corticotropin-releasing hormone (CRH)
gene, mRNA (1400 nucleotides), and protein precursor (187 amino acids). The exons
of the gene are shown as blocks. The intron, 5'- and 3'-flanking sequences are
shown as lines. The 5'- and 3'-untranslated regions are shaded. The cAMPresponsive element (CRE) is indicated. The location of the CRH peptide is indicated
by CRH (adapted from Thompson et al., 1987).

concomitantly following blockade of corticosterone synthesis with metyrapone
(Herman et al., 1992).

Localization of CRH Neurons
The PVN is composed of a cluster of neurons that lie dorsally along the third
ventricle (see Figure 3). The PVN contains at least three functionally and
anatomically distinct groups of neurons (see Figure 4; for rev. see Swanson, _1987).
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PVN
Figure 3. The paraventricular nucleus of the hypothalamus (Interaural 7.20 mm,
Bregma -1.80 mm; adapted from Paxinos and Watson, 1986).

The parvocellular neurosecretory group consists of neurons that project to the
neurohemal zone of the median eminence, where they release hormones into the
hypophysial portal circulation. These cells are found in the dorsal medial
parvocellular and periventricular subdivisions of the PVN. The magnocellular
neurosecretory group consists of large neurons whose axons project to the posterior
pituitary where they release vasopressin and oxytocin into the general circulation.
These neurons are concentrated in the anterior, medial, and posterior magnocellular
subdivisions of the PVN. The third group of neurons are localized to the dorsal,
ventral medial and lateral parvocellular subdivisions of the PVN. These neurons give
rise to descending projections to other areas of the hypothalamus, the brainstem and
the spinal cord. These neurons are believed to influence the autonomic nervous
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Figure 4. The subdivisions of the paraventricular nucleus of the hypothalamus
(PVN). Frontal sections are arranged from rostral (A) to caudal (F). AHA, anterior
hypothalamic area; am, anterior magnocellular part of the PVN; ap, anterior
parvocellular part of the PVN; BNSTP, bed nucleus of the stria terminalis (preoptic
part); dp, dorsal parvocellular part of the PVN; f, fornix; lp, lateral parvocellular part
of the PVN; met, medial cortico-hypothalamic tract; mp, medial parvocellular part of
the PVN; pm, posterior magnocellular part of the PVN; pv, periventricular part of the
PVN; ZI, zona incerta (adapted from Swanson, 1987).
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system, the output of the central gray and reticular formation, and the central relay of

visceral and nociceptive information.
CRH containing neurons are found in all 8 divisions of the PVN, however
most are found in the dorsal medial parvocellular part (for rev. see Sawchenko and
Swanson, 1990). The axons of these cells project laterally around the fornix and end

in the neurohemal zone of the median eminence where CRH is released into the
hypophysial portal blood.
CRH neurons are found in many other areas of the central nervous system.
Other hypothalamic sites in which CRH-IR cells have been observed include the
arcuate, periventricular, premammillary, preoptic, supraoptic, and suprachiasmatic
nuclei (for rev. see Sawchenko and Swanson, 1990). The majority of the projection
fields of these CRH-IR cells are unknown. Extrahypothalamic brain areas containing
CRH neurons include a dense cluster of CRH neurons within the central nucleus of
the amygdala (CeA) and in the bed nucleus of the stria terminalis (BNST; Swanson

et al., 1983; Moga and Gray, 1985; Gray and Magnuson, 1987). Although the
function of these cells has not been fully characterized, these neurons may serve to
coordinate endocrine, autonomic, and behavioral responses to stress (for rev. see
Menughi et al., 1993).
Localiution of CRH mRNA coincides with immunocytochemical data of
peptide locali7.at.ion. Using in situ hybridiution histochemistry (ISHH), CRH mRNA
was observed in both the parvocellular and magnocellular regions of the PVN as well
as in the supraoptic nucleus of the hypothalamus (Young et al., 1986a; Lightman and
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young, 1987). Additionally, Northern blot analysis has revealed CRH mRNA in
RNA extracted from the PVN, amygdala, BNST, and supraoptic nucleus (Beyer et

al., 1988).
Other neuropeptides including AVP are localized within various subsets of the
parvocellular PVN CRH neurons. Furthermore, adrenalectomy induces expression of
AVP in the majority of CRH cells in the PVN (Roth, et al., 1982; Sawchenko, et al.,
1984), and the ratio of AVP: CRH release from the median eminence in vitro
increases from 2: 1 in the intact rat to 8: 1 in adrenalectomized animals (Holmes et al.,
1986). This could be important since AVP is believed to potentiate the effect of CRH
on ACTH secretion. In addition, oxytocin (Sawchenko et al., 1984), neurotensin
(Ceccatelli et al., 1989b), dynorphin (Roth et al., 1983), enkephalin (Ceccatelli et al.,
1989b; Hokfelt et al., 1983), and enkephalin mRNA (Pretel and Piekut, 1990) have
been localized within CRH neurons in the PVN. The function of these colocalized
peptides is unknown, but one peptide may influence the action of the other at the level
of the anterior pituitary.

Neuroanatomical Inputs to the PVN
The neuroanatomical inputs to the PVN arise from both extrahypothalamic and
intrahypothalamic sources (for rev. see Swanson and Sawchenko, 1983; Swanson,
1987; Palkovits, 1987). Extrahypothalamic inputs are derived from three general
systems: the limbic system, the lower brain stem, and the circumventricular organs
(see Figure 5). Limbic system structures which influence the PVN include the
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hipp<>CaIIlPUS (subiculum), the amygdala, and the septum. Most of these structures do

not send direct pathways to the PVN but rather relay through the septum, the bed
nucleus of the stria terminalis, or various hypothalamic nuclei (Sawchenko and
Swanson, 1983).
Lower brainstem inputs to the PVN originate from the raphe nuclei, the locus
coeruleus, the parabrachial nucleus, the nucleus of the solitary tract, and the reticular
formation. Cells in the lateral reticular nucleus (Al-Cl cells in the ventrolateral
medulla), the medial part of the nucleus of the solitary tract (A2-C2 cells in the
dorsomedial medulla), and the locus coeruleus (A6 cell group) give rise to the
majority of the noradrenergic and adrenergic innervation of the PVN (Palkovits et al. ,
1980a; Palkovits et al., 1980b; Sawchenko and Swanson, 1982; Kiss et al., 1983).
The axons of these cells ascend via a periventricular route or via the ventral tegmental
bundle-medial forebrain bundle system or to the PVN. Serotoninergic innervation of
the PVN originates from the median and dorsal raphe nuclei (Sawchenko et al., 1983;
Palkovits et al., 1977).
Circumventricular organ innervation of the PVN arises from the subfomical
organ and the organum vasculosum lamina terminalis. The pathway from the
subfomical organ to the PVN contains angiotensin TI immunoreactivity (Lind et al. ,
1984) and is activated by hemorrhage (Abdelaal et al., 1974; Mangiapani and
Simpson, 1980; Knepel et al., 1982; Lind et al., 1983). Thus, subfomical organ
innervation of the PVN is likely to be involved in the release of CRH, vasopressin,
and oxytocin during hypovolemia (Swanson, 1987).
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IX,X

Figure 5. Summary of major neural inputs to the paraventricular nucleus of the
hypothalamus (PVN). Limbic system inputs include projections from the
hippocampus and amygdala. Al, Al-Cl cells in the ventrolateral medulla; BNST,
bed nucleus of the stria terminalis; HYP, various hypothalamic nuclei; IX,
glossopharyngeal nerve; NTS, nucleus of the solitary tract; PBN, parabrachial
nucleus; R, raphe nuclei; SEP, septum; SFO, subfornical organ; X, vagus nerve
(adapted from Swanson, 1987).

Intrahypothalamic inputs to the PVN arise from almost all of the hypothalamic
and preoptic nuclei (Swanson and Cowan, 1975; Swanson, 1976; Saper et al., 1976;
Saper et al., 1978; Saper et al., 1979; Silverman et al., 1981). Currently, most of
this innervation has not been neurochemically characterized. Those inputs that have
been characterized are peptidergic, using transmitters such as angiotensin II and
neuropeptide Y (Bai et al., 1985). Using electron microscopic immunocytochemistry, ·
synaptic specializations between magnocellular neural processes and CRH-IR
perikarya have been observed (Leranth et al., 1983). Thus, it is likely that
magnocellular neurons within the PVN (probably containing vasopressin or

o~ytocin)
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also innervate CRH neurons.
Signals indicating the existence of physical and psychological stress reach the
pVN via multiple neural pathways. Anatomical and physiological evidence suggest
that somatosensory and viscerosensory information reaches the PVN via multisynaptic neural pathways (Palkovits, 1987; Swanson, 1987). This information reaches
the medullary and pontine reticular formation and biogenic amine containing cells
groups. Projections from these cells ascend to the PVN via the ventral tegmental
tract and medial forebrain bundle. For example, the nucleus of the solitary tract
receives visceral information from the vagus and glossopharyngeal cranial nerves.
These signals are then conveyed to the PVN. This example is probably the most
direct route to the PVN for viscerosensory information. In contrast, psychogenic
stress probably requires neural processing in the cerebral cortex (Swanson, 1987).

This cognitive information is then carried to limbic regions such as the hippocampus
and amygdala. The hippocampus and amygdala then relay the signals to the PVN.
Although direct innervation of the PVN from the amygdala has been demonstrated
(Gray et al., 1989) both the hippocampus and amygdala send indirect connections to
the PVN via the septum and bed nucleus of the stria terminalis (Swanson, 1987;
Cullinan et al., 1993).

Neurotransmitters Influencing CRH Secretion
Several neurotransmitter systems are believed to influence the secretion of
CRH from parvocellular PVN neurons (for rev. see Tsagarakis and Grossman, 1990;
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Table 1. Neurotransmitters that control hypothalamic CRH release.

STIMULATORY

Acetylcholine
Norepinepherine
Serotonin
Angiotensin II
Neuropeptide Y
Activin

INHIBITORY

GABA
Opioids
Substance P
Atrial Natriuretic Peptide
Vasopressin

Whitnall, 1993). In general, acetylcholine, catecholamines, serotonin, and some
neuropeptides such as angiotensin II and neuropeptide Y are believed to have a
stimulatory effect on hypothalamic CRH secretion. In contrast, gamma-aminobutyric
acid (GABA), endogenous opioids, and neuropeptides such as substance Pare thought
to inhibit secretion of CRH into the hypophysial portal blood. These neurotransmitter
effects on hypothalamic CRH release are summarized in Table 1.
A great deal of evidence supports a stimulatory effect of acetylcholine on
ACTH secretion. Intracerebroventricular injection or median eminence implantation
of the cholinergic agonist, carbachol, yielded an increase in plasma CORT levels
(Krieger and Krieger, 1970; Abe and Hiroshige, 1974). Furthermore, implantation of
the cholinergic antagonist atropine rostral to the PVN was found to decrease the
ACTH responses to surgical and ether stress (Hedge and Smelik, 1968; Hedge and De
Wied, 1971). In vitro studies using hypothalamic explants indicated that
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administration of acetylcholine increased CRH bioactivity and CRH as measured by
radioimmunoassay (Hillhouse et al., 1975; Buckingham and Hodges, 1979; Suda et

al., 1987; Tsagarakis et al., 1988; Calogero et al., 1988a). In vivo, administration of
acetylcholine resulted in an increase in hypophysial portal CRH in anesthetized rats
(Plotsky et al., 1987). Both nicotinic and muscarinic receptors may be involved in
this response although the muscarinic response is probably the dominant one
(Tsagarakis et al., 1988). This is consistent with the distribution of cholinergic
receptors as the muscarinic receptor is more predominant in the hypothalamus (Dolly
and Barnard, 1984).
The effect of catecholamines on hypothalamic CRH secretion is somewhat
controversial (for rev. see Plotsky et al., 1989; Whitnall, 1993). However, the
strongest evidence indicates that catecholamines stimulate HPA activity.
Administration of norepinepherine to rats under basal conditions increases circulating
ACTH (Szafarcayk et al., 1987; Plotsky et al., 1987; Guillaume et al., 1987).
Electrical or chemical activation of catecholaminergic afferent pathways to the
hypothalamus yields increases in CRH, ACTH, and CORT secretion while blockade
or destruction of these pathways decreases HPA activity (Plotsky et al., 1989). In
vitro, norepinepherine stimulation of CRH secretion is blocked by /3-adrenergic
antagonists (Tsagarakis et al., 1988). This implicates the /3-adrenergic receptor in the
stimulatory effect of catecholamines on CRH secretion. Norepinepherine can also
increase adrenocortical secretion through an ai-adrenergic receptor-mediated event
(Al-Damluji et al., 1987; Plotsky, 1987; Calogero et al., 1988b; Al-Damluji et al.,
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l990). However, this response is thought to be the result of an increased secretion of
vasopressin (a potent CRF) from the hypothalamus rather than CRH (Al-Damluji et

al., 1990). Activation of a 2-adrenergic receptors results in an inhibition of CRH
secretion (Al-Damluji, 1988). This is believed to be the result of presynaptic binding
of a 2-receptor agonists causing a decrease in catecholamine release (Smythe et al. ,
1983).
Several studies have demonstrated that activation of central 5HT1 and 5HT2
serotonin receptors enhances HPA activity (Szafarczyk et al., 1979; Bagdy et al.,
1989; Golden et al., 1989; Alper, 1990; Di Sciullo et al., 1990; Fuller, 1990;
Gartside and Cowen, 1990; Matsuda et al., 1990; Bagdy et al., 1991). In vitro
studies report increases in bioassayable CRF (Jones and Hillhouse, 1977; Buckingham
and Hodges, 1979) and in CRH (Nakagami et al., 1986; Calogero et al., 1989;
Hillhouse and Milton, 1989; Spinedi and Gaillard, 1991) following administration of
serotonin to hypothalamic explants or long term hypothalamic cultures (Nakagami et

al., 1986; Calogero et al., 1989). In addition, serotonin has been shown to increase
CRH secretion in vivo (Gibbs and Vale, 1983). Thus, strong evidence exists
implicating a stimulatory effect of serotonin on HPA function at the level of the
hypothalamus.

In vivo studies demonstrate that GABA and GABA receptor agonists inhibit
and GABA receptor antagonists enhance stress-induced HPA activity (Makara and
Stark, 1974). GABA receptor antagonists have also been shown to stimulate
adrenocortical secretion under basal conditions (Makara and Stark, 1974). Similarly,
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intraeerebroventricular injection of GABA and GABA receptor agonists increased
hypothalamic CRH secretion (Makara and Stark, 1974). Furthermore, stimulated

release of both bioassayable corticotropin-releasing activity and CRH (as measured by
radioimmunoassay) were inhibited by GABA in vitro (Jones and Hillhouse, 1977;
Buckingham and Hodges, 1979; Calogero et al., 1988c; Tsagarakis et al., 1990a).
There is a dense network of GABA-ergic fibers surrounding the PVN (Meister et al. ,
1988). Also, GABA is co-stored and co-released from CRH neurons and may act on
presynaptic receptors in the median eminence (Meister et al. , 1988). It is therefore
likely that GABA is an important inhibitor of hypothalamic CRH release.
Endogenous opioids are generally believed to be inhibitory with respect to
their effects on hypothalamic CRH secretion. In vitro, several opioids have been
shown to decrease CRH secretion stimulated by neurotransmitters or depolarizing
agents (Tsagarakis et al., 1989a; Tsagarakis et al., 1990b). Furthermore,
administration of opioid receptor antagonists significantly increases basal CRH
secretion. In anesthetized rats, opioid administration decreases hypophysial portal
CRH and nitroprusside-induced CRH release (Plotsky, 1986). Thus, endogenous
opioids may serve to maintain an inhibitory tone upon CRH release. This is believed
to involve kappa- and possibly mu-, but not delta-opioid receptors (Tsagarakis and

Grossman, 1990; Whitnall, 1993).
Several neuropeptides have been demonstrated to influence HP A activity and
CRH secretion. In vivo and in vitro studies suggest that angiotensin II (Plotsky et al. ,
1988), neuropeptide Y (Wahlestedt et al., 1987; Haas and George, 1987; Tsagarakis
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et al., 1989b), and activin (Plotsky et al., 1991) are stimulatory in this respect while
atrial natriuretic peptide (Takao et al., 1988; Ibanez-Santos et al., 1990), substance P
(Chowdrey et al., 1990; Faria et al., 1991), and vasopressin (Plotsky et al., 1984)
are inhibitory. The inhibition of HPA activity by vasopressin appears paradoxical
since vasopressin also has corticotropin-releasing activity. However, this may be one
mechanism by which the system is kept in check.

Effects of Stress/Feedback on CRH Neurons
Stress and Glucocorticoids
Following stress, glucocorticoids act at the levels of the pituitary,
hypothalamus, and extrahypothalamic loci within the brain to return HPA activity to
homeostatic levels. This feedback inhibition has been a topic of intense research and
has been extensively reviewed (Keller-Wood and Dallman, 1984; Jones and Gillham,
1988). This review will focus only on glucocorticoid feedback inhibition at (or
above) the level of the hypothalamus. The data presented in this section are
summarized in Table 2.
Corticosteroid feedback on CRH secretion has been demonstrated by the
examination of the effects of adrenalectomy and/or the treatment with exogenous
glucocorticoids on basal and stress-induced CRH activity. Adrenalectomy-induced
increases in CRH and AVP immunoreactivity in parvocellular neurosecretory neurons
are inhibited by systemic glucocorticoid replacement (Sawchenko, 1987a; Itoi et al.,
1987). Dexamethasone blocks increases in hypophysial portal vessel concentrations of
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CRH-induced by hemorrhage stress (Plotsky and Vale, 1984), and plasma CORT
levels between 80 and 120 ng/ml suppress hypotensive stress-induced increases in
CRH release (Plotsky et al., 1986). Conversely, adrenalectomy increases CRH and
AVP concentrations in hypophysial portal plasma 3 weeks following surgery (Fink et

al., 1988). Pharmacological adrenalectomy using metyrapone or aminoglutathimide
leads to a decrease in secretion of CRH and AVP in the initial 12-24 hours but an
increase in CRH release by 72 hours (Plotsky and Sawchenko, 1987). The decrease
probably reflects an initial depletion of releasable CRH pools while the subsequent
increase represents the removal of inhibition by adrenal glucocorticoids.
Furthermore, secretion of CRH from cultured hypothalami can be inhibited by CRH,
ACTH, and dexamethasone (Calogero et al., 1988d; Suda et al., 1986). These
studies demonstrate a hypothalamic locus for negative feedback regulation of the HPA
axis but do not, however, indicate whether changes in synthesis, storage, or release of
hypothalamic CRF's explain this phenomenon.
To further characterize the role of the hypothalamus in the negative feedback
of the HPA axis, several investigators have studied the effects of stress,
adrenalectomy, and glucocorticoids on CRH and AVP gene expression. CRH mRNA
(Young et al., 1986a; Kovacs and Mezey, 1987; Lightman and Young, 1989; Beyer

et al., 1988; Imaki et al., 1991; Almeida et al., 1992) and AVP mRNA (Young et
al., 1986b) increase in the parvocellular PVN following adrenalectomy. These
increases are abolished by glucocorticoid replacement (Lightman and Young, 1989;
Kovacs and Mezey 1987; Beyer et al., 1988; Imaki et al., 1991). This response to
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Table 2. Effect of stress, adrenalectomy and glucocorticoid treatment on
hypothalamic corticotropin-releasing hormone (CRH) and
vasopressin (A VP).
TREATMENT

EFFECT

MEASUREMENT

REFERENCES

increases CRH-IR and A VP-IR
in parvocellular PVN
CRH mRNA and
AVPrnRNA
decreases parvocellular PVN

Sawchenko, 1987; Itoi et al.,
1987
Young et al., 1986a; Kovacs
and Mezey, 1987; Lightman
and Young, 1989;
Beyer et al., 1988; Imaki et
al., 1991; Almeida et al.,
1992; Young et al., 1986b
Plotsky and Vale, 1984

Dexamethasone

increases Hypophysial portal
CRH
decreases

Hypotensive stress

mcreases

Plotsky et al., 1986

Adrenalectomy

Glucocorticoid
replacement

Hemorrhage stress

Plasma corticosterone decreases
(80-120 ng/rnl)
Adrenalectomy

mcreases Hypophysial portal
CRH and A VP
Metyrapone (12-24h) decreases

Fink et al., 1988
Plotsky and Sawchenko,
1987

Metyrapone (72h)

increases

CRH
ACTH

decreases Secretion of CRH
from cultured
decreases hypothalami

Dexamethasone

decreases

Hypertonic saline
stress

increases CRH mRNA levels in Lightman and Young, 1988;
PVN
Lightman and Young, 1989

+Adrenalectomy

increases

+Dexamethasone decreases

Calogero et al., 1988; Suda et
al., 1986
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a&enaiectomy and glucocorticoid replacement appears to be specific to the
parvocellular PVN as magnocellular AVP mRNA (Young et al., 1986b) and CRH
mRNA in the BNST and CeA (Beyer et al., 1988) are not affected. CRH mRNA and
AVP mRNA also increase in the medial parvocellular region of the PVN within 4
hours of hypertonic saline stress (Lightman and Young, 1988; Lightman and Young,
1989). This may represent an increase in synthesis of CRH to replenish CRH stores
released during stress. Hypertonic saline stress leads to greater increases in CRH
mRNA in the PVN in the absence of negative feedback, i.e. in adrenalectomized
animals as compared to intacts (Lightman and Young, 1989). Furthermore,
dexamethasone-treatment attenuates basal and stress-induced increases in CRH mRNA
levels (Lightman and Young, 1989). Thus, changes in CRH and AVP gene
expression may be associated with the negative feedback of the HPA axis following
stress.

Corticosteroid Receptors
Adrenocorticosteroids exert their effects by binding one of two intracellular
receptors (for rev. see DeKloet et al., 1987). These receptors have been given the
designations type I and type II corticosteroid receptors. The two receptor subtypes
differ from each other in their anatomical distribution, their pharmacalogical
properties, and their function. The type I receptor, or mineralocorticoid receptor, is
localized predominantly in the hippocampus and septum (McEwen et al., 1968; Reul
and DeKloet, 1985; Van Eekelen et al., 1988; Arriza et al., 1988; Herman et al.,
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!989). This receptor binds with a very high affinity to CORT, aldosterone, and
dexamethasone (Beaumont and Fanestil, 1983; Krosowski and Funder, 1983; Reul and
oeKloet, 1985; Allen et al., 1988; Brinton and McEwen, 1988). Because of this
high affinity binding, the mineralocorticoid receptor is functionally important when
plasma corticosteroids are low. Thus, the mineralocorticoid receptor is believed to be
involved in tonic and permissive functions. These include the regulation of
exploration (Veldhuis and DeKloet, 1983), food seeking (Jhanwar-Uniyal et al.,
1986), and basal (i.e., circadian) HPA activity (Dallman et al., 1989; Ratka et al.,
1989).
The type II receptor, or glucocorticoid receptor, is localized in glial cells and
neurons throughout the central nervous system (Fuxe et al., 1985; Reul and DeKloet,
1985; Reul and DeKloet, 1986; Van Eekelen, et al., 1987; Aronsson et al., 1988;
Sarrieau et al., 1988; Van Eekelen et al., 1988; Ceccatelli et al., 1989c; Herman, et

al., 1989; Sousa et al., 1989). The regions of highest concentration of glucocorticoid
receptor include the hippocampus, PVN, lateral septum, central amygdala, arcuate
nucleus, and supraoptic nucleus. The glucocorticoid receptor also binds CORT and
dexamethasone but with lower affinity than the mineralocorticoid receptor (Krosowski
and Funder, 1983; Reul and DeKloet, 1985; Brinton and McEwen, 1988). Because
the glucocorticoid receptor binds CORT with a low affinity, this receptor is only
occupied when plasma CORT levels are high. Thus, the glucocorticoid receptor is
thought to be involved in the regulation of behavioral, neuroendocrine, and autonomic
responses to stress and participates in the negative feedback inhibition of HPA activity
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following stress (Reul and DeKloet, 1985).

Neuroanatomica1 Locus of Feedback Inhibition
There is significant evidence implicating the hippocampus, which contains both
CORT receptor types, in the regulation of the HPA axis (for rev. see Jacobsen and
Sapolsky, 1991). Most experiments indicate that the role of the hippocampus in this
respect is inhibitory in nature. For example, electrical stimulation of the
hippocampus decreases plasma CORT levels (Mandell et al., 1963; Rubin et al.,
1966), and fornix transection or hippocampectomy results in increased plasma CORT
levels (Nakadate and DeGroot, 1963; Wilson et al., 1980). Furthermore,
hippocampal stimulation inhibits and hippocampal lesion augments the CORT
secretion induced by exposure to a stressor (Dupont et al., 1972, Kawakami et al.,
1968). The hippocampus is also implicated in the termination of HPA responses to
stress in that secretion of CORT persists much longer after exposure to restraint stress
in rats with kainate lesions of the hippocampus (Sapolsky et al., 1984a).
In addition to the role of the hippocampus in the negative feedback response of
glucocorticoids, the PVN remains a probable site of direct glucocorticoid action in
this respect. Immunocytochemical studies reveal the presence of glucocorticoid
receptors in CRH-containing neurons in the PVN (Ceccatelli et al., 1989c).
Furthermore, unilateral implantation of dexamethasone into the PVN inhibits the
adrenalectomy-induced increases in CRH and AVP immunoreactivity (Kovacs et al.,
1986; Sawchenko, 1987b) and in CRH mRNA (Kovacs and Mezey, 1987) on. the
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implanted side. Interestingly, these studies reported that implantation of
dexamethasone into the hippocampus resulted in a slight decrease in the
adrenalectomy-induced effects on CRH and AVP immunoreactivity (Kovacs et al.,
1986) while no effect was seen on CRH mRNA (Kovacs and Mezey, 1987).

The Hypothalamo-Pituitary-Gonadal Axis
The hypothalamo-pituitary-gonadal axis is an essential element of reproductive
function. A subset of hypothalamic neurons synthesize gonadotropin-releasing
hormone (GnRH) which is also known as leutenizing hormone releasing hormone
(LHRH). These neurons project to the median eminence where they secrete GnRH
episodically into the hypophysial portal vasculature (for rev. see Marshall et al. ,
1992; Pfaff et al., 1994). Gonadotropin-releasing hormone stimulates gonadotroph
cells of the anterior pituitary to synthesize and secrete leutenizing hormone (LH) and
follicle-stimulating hormone (FSH). In the male, leutenizing hormone stimulates
Leydig cells of the testes to produce and secrete testosterone. Testosterone is
necessary for spermatogenesis, reproductive behavior, and the development of male
secondary sex characteristics. In addition, testosterone feeds back on the brain and
pituitray to reduce HPG axis activity (Petraglia et al., 1984; Bhanot and Wilkinson,
1985; Gabriel et al., 1986; Wehrenberg et al., 1989; Kalra et al., 1990; Sahu et al.,
1990; Huang and Harlan, 1993).
Products of the HPA axis have been shown to inhibit reproductive function.
Several studies have demonstrated that CRH attenuates hypothalamic GnRH secretion
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(Rivier and Vale, 1984; Rivier and Vale 1985b; Rivier et al., 1986). Furthermore,
ACTH and corticosterone act on the hypothalamus, pituitary, and gonads to decrease
HPG axis activity (Vreeburg et al., 1984; Kamel and Kubajak, 1987; Mann et al.,
1987). Moreover, products of the HPA axis suppress reproductive behaviors (PlasRose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986; Sirinathsinghji

et al., 1986).

Effects of Gonadal Steroids on the HPA Axis
Previous studies have demonstrated a significant sex difference in circulating
CORT levels and in the CORT response to stress with females having higher levels
than males (Kitay, 1961). Since then, several studies have focused on the role of
estrogen in this sex difference (Kitay, 1963; Telegdy et al., 1964; Raps et al., 1971;
Pollard et al., 1975; Ramaley, 1976; Buckingham et al., 1978; Phillips and
Poolsanguan, 1978; Burgess and Handa, 1992). These studies demonstrate that basal
CORT levels are decreased in ovariectomized rats as compared to ovariectomized rats
receiving estrogen replacement (Kitay, 1963; Telegdy et al., 1964; Ramaley, 1976;
Lesniewska et al., 1990). In addition, basal CORT as well as stress-induced CORT
and ACTH levels vary with the estrous cycle (Raps et al., 1971; Pollard et al., 1975;
Buckingham et al., 1978; Phillips and Poolsanguan, 1978; Viau and Meaney, 199la).
ACTH and CORT levels are greatest on proestrous when estrogen levels are highest.
A number of studies have suggested that estrogen influences HPA activity, at
least in part, at the level of the PVN. Chronic estrogen treatment of ovariectomized
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female rats significantly reduced hypothalamic CRH content as determined by
radioimmunoassay of hypothalamic extracts (Haas and George, 1988). A subsequent
study suggested that this decrease in hypothalamic CRH content was the result of an
inhibition of CRH synthesis (Haas and George, 1989). CRH mRNA in the
parvocellular PVN has also been shown to vary across the estrous cycle (Bohler et

al., 1990). CRH mRNA is elevated on the afternoon of proestrous, at the time of the
estrogen-induced midcycle surge of luteinizing hormone.
Fewer studies have focused on the effects of testosterone on the HPA axis.
Gonadectomy of the male rat and hamster leads to enhanced levels of CORT
correlating with increases in ACTH bioactivity (Critchlow et al., 1963; Gaskin and
Kitay, 1971). Following foot shock stress or exposure to a novel environment,
plasma CORT and ACTH levels are higher in gonadectomized male rats as compared
to intact animals (Handa et al., 1994). Gonadectomized rats receiving replacement
testosterone (T) or the non-aromatizable androgen, dihydrotestosterone (DHT), have
post-stress plasma CORT and ACTH levels similar to that seen in intact animals
(Handa et al., 1994). These data suggest that, in contrast to the effects of estrogen,
androgens act to inhibit the CORT and ACTH responses to stressful stimuli.

Gonadal Regulation of AVP Expression
Aside from the neurohypophysial neurons of the PVN that secrete AVP into
the portal vasculature, a number of AVP-immunoreactive neuronal pathways have
been demonstrated in the rat brain (Buijs, 1978). These AVP fibers arise from AVP-
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IR cell bodies in the PVN (Devries and Buijs, 1983; Sawchenko and Swanson,
1982), BNST (DeVries and Buijs, 1984), medial amygdala (MeA; Caffe et al., 1987),
and suprachiasmatic nucleus (Hoomeman and Buijs, 1982).
A sex difference in AVP fiber density has been demonstrated. The density of
AVP fibers in the lateral septum and lateral habenular nucleus is higher in males than
in females (DeVries et al., 1981). Lesioning and tracing studies indicate that the
origin of these fibers probably lies in the BNST (DeVries and Buijs, 1984). This sex
difference is dependent on the neonatal presence of testosterone (DeVries et al.,
1983). In the adult animal, androgens appear to maintain this sex difference since
gonadectomy of male rats has been shown to lead to a disappearance of AVP-IR cell
bodies and AVP mRNA in the BNST and MeA without affecting AVP-IR cell bodies
in the PVN (DeVries et al., 1985; Miller et al., 1992). Furthermore, androgen
receptor immunoreactivity has been localized within AVP-expressing cells of the
BNST and MeA (Zhou et al., 1994).
Similarly, AVP fiber density in several brain regions including the MeA,
lateral septum, and lateral habenular nucleus has been shown to decrease in the aged
rat (Fliers et al., 1985). In the rat, plasma T levels decline with age (Kaler and
Neaves, 1981). When plasma T levels in aged rats were restored to that of young
animals AVP fiber density was also restored (Goudsmit et al., 1988). This evidence
coupled with evidence that androgen and estrogen receptors are found within neurons
of the BNST and MeA (Wood et al., 1992; Wood and Newman, 1993; Don Carlos et

al., 1991; Tobet et al., 1993) supports a role for gonadal hormones in the regulation
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of A VP expression in some brain regions.
While these data demonstrate that androgens can regulate neuropeptides,
changes in the A VP system would not explain changes in the CORT and ACTH
responses to stress noted in the castrated male rat. DeVries, et al. (1985) report that
castration did not affect the number of A VP-IR cell bodies in the PVN, and changes

in AVP-IR cell bodies in other brain regions were in the wrong direction to explain
androgen influences on the HPA response to stress.

Mechanism of Steroid Action
Signal Transduction
Gonadal steroids initiate changes in cellular function via specific intracellular
receptors which act as ligand-responsive transcription factors (for rev. see Blaustein,
1985; Evans, 1988). The gonadal and adrenal steroid receptors have been grouped in
a "superfamily" of intracellular receptors due to the similar function and high degree
of sequence homology among these receptors (for rev. see Evans, 1988). This
receptor superfamily includes receptors for vitamin D, thyroid hormone, retinoic acid,
and the retroviral oncogene product, v-erb A. (The mechanism of steroid receptor
action is depicted in Figure 6).
Previously, it was believed that unoccupied steroid receptors may be localized
in the cytoplasm and may need to be translocated into the cell's nucleus following
ligand binding. Recent data, however, suggest that unoccupied receptors may be
localized within the cell nuclei (Sheridan et al., 1979; King and Greene, 1984;
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Welshons et al., 1984; Gase et al., 1989; Zhuang et al., 1992; Pekki et al., 1992).
These unbound receptors are found complexed with two 90 kiloDalton heat shock
protein (hsp90) molecules (Catelli et al., 1985; Sanchez et al., 1985; Mendel and

Orti, 1988). The function of hsp90 may be related to protein folding, transport,
and/or stabilization (Pratt, 1990). Other heat shock proteins, hsp59 and hsp70, also
participate in this multiprotein complex (Sanchez, 1990; Muller and Renkawitz, 1991)
although their functions are currently unknown. The inactive complex is loosely
bound to nuclear chromatin.
When the hormone binds to its high affinity binding site on the receptor
molecule, hsp90 dissociates. The receptor-ligand complex can then become tightly
bound to DNA. When bound to its ligand, an intracellular receptor alters gene
expression of specific steroid-responsive genes. Steroid-responsive genes contain
short (about 20 base pairs) cis-acting sequences or hormone response elements
(HREs) that are required for hormonal activation of the gene (Govindan et al., 1982;
Scheidereit et al., 1983; Karin et al., 1984). These HREs function in a position- and
orientation-independent fashion as transcriptional enhancers (Chandler et al., 1983).
Thus, transcriptional regulation depends on the binding of hormone-receptor
complexes to HRE sites on DNA. Identification of HRE sequences reveals an
apparent dyad symmetry implying that HREs interact with receptor dimers (Waterman

et al., 1988; Chalepakis et al., 1990).
Hormone-receptor coupling is also necessary for induction of the receptors
trans-activation function (Webster et al., 1988). The ligand-receptor complex- alters
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gene transcription by interacting with other components regulating transcription. For
example, ligand-activated steroid receptors have been shown to interact with the factor
which binds to a consensus sequence, the TATA box, found within many promoter
regions (Ptashne, 1988; Ham et al., 1988).
Steroid receptors have been shown to interact with other transcription factors
as well (Schule et al., 1988; Strahle et al., 1988). For example, binding of the
glucocorticoid receptor to its HRE enhances the transcription induced by the binding
of another factor to its binding site, a CACCC-box (Schule et al., 1988). This
synergism is dependent upon a distance of 10 base pairs between the binding sites.
Ten base pairs corresponds to one tum of the double helix. Thus, a stereo-specific
alignment and a protein-protein interaction between the receptor-ligand complex and
the other transcription factor is likely.
In addition to the positive regulation of gene expression outlined above, steroid
hormone receptors can negatively regulate gene expression. Various mechanisms by
which intracellular receptors repress gene expression have been described. First,
binding of a receptor-ligand complex to its HRE can displace a positive regulatory
factor (Akerbloom et al., 1988; Guertin et al., 1988; Sakai et al., 1988; Beato, 1989;
Drouin et al., 1989). For example, the occupied glucocorticoid receptor represses
expression of the human glycoprotein a-subunit gene because the glucocorticoid
response element overlaps a functional cAMP response element (Akerbloom et al.,
1988). Thus, binding of the glucocorticoid receptor to its HRE sterically hinders the
binding of the positive transcription factor to the cAMP response element.

Altered cellular function
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Figure 6. Pathway of signal transduction of intracellular steroid receptors. The
steroid (S) diffuses through the cell membrane where it binds to the receptor (R)
which is complexed to heat shock proteins (hsp). The hsp molecules dissociate, and
the steroid-receptor complex binds DNA as a homodimer. Binding of the receptorligand complex can lead to transcription of mRNA's, translation of proteins, and
ultimately an alteration of cellular function.

A second mechanism by which steroid receptors negatively regulate gene
expression involves the regulation of AP-1 mediated induction of gene expression (see
Figure 7). AP-1 is a transcriptional activator composed of protein dimers of jun and
fos gene family products. Both Jun-Fos heterodimers and Jun-Jun and Fos-Fos
homodimers are capable of binding the AP-1 site and inducing gene expression
(Diamond et al., 1990). However, the Jun-Fos heterodimer binds with higher
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Figure 7. A model of glucocorticoid regulation of AP- I-mediated transcription of the
proliferin gene. In each panel the solid line represents the DNA surrounding the
promoter. The different sized arrows depict relative levels of transcriptional activity.
In the absence of AP-1 activity the glucocorticoid-receptor complex (GR) does not
influence transcription (A,B). The Jun homodimer activates transcription (C). The
GR enhances Jun homodimer-induced transcription (D). The Jun-Fos heterodimer
strongly activates transcription (E). However, the GR reduces heterodimer-induced
transcription (F); (adapted from Diamond et al., 1990).

affinity and more strongly activates gene expression compared to the homodimers.
Glucocorticoids can both positively and negatively regulate the AP-1 mediated
induction of the proliferin gene (Diamond et al., 1990). The positive and negative
regulation of gene expression by glucocorticoids depends upon the intracellular ratio
of Jun and Fos. The synthetic glucocorticoid, dexamethasone, enhances the
expression of proliferin activated by Jun homodimers. However, dexamethasone
reduces Fos homodimer- and Fos/Jun heterodimer-induced gene expression. Thus,
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interaction of the glucocorticoid receptor with Jun homodimers results in positive gene
regulation while interaction of the glucocorticoid receptor with Fos/Jun heterodimers
results in negative regulation of the gene (Diamond et al., 1990). Recently, it was
demonstrated that binding of the glucocorticoid receptor to the transcription factor,
AP-1, results in a repression of AP-1 stimulated expression of the collagenase gene
(Jonat et al., 1990). This direct interaction of a receptor-ligand complex with a
transcription factor occurs in the absence of DNA binding. Thus, it appears that an
AP-11glucocorticoid receptor complex is formed which is unable to trans-activate.
The mechanism by which specific hormonal regulation of gene transcription is
attained in vivo has been a fundamental question in the field of steroid receptor
biology. This is because in vitro several receptors can bind the same DNA binding
sites (Cato et al., 1988; Ham et al., 1988). For example, glucocorticoids and
androgens recognize a common HRE. Recent studies have indicated the presence of a
complex, 120 base pair enhancer of the mouse sex-limited protein (Slp) gene that is
activated exclusively by androgens and not by glucocorticoids in transfection (Adler et

al., 1991; Adler et al., 1992; Adler et al., 1993). Hormonal specificity is enforced
by non-receptor elements within the enhancer (Adler et al., 1992). Androgen-specific
activation occurs when ligand-activated androgen receptor binds the consensus HRE
site and interacts with a specific factor on the enhancer to activate transcription (Adler

et al., 1992). Glucocorticoid receptor may bind the HRE but is unable to
transactivate (Adler et al., 1992). Selectivity appears to be dependent upon the amino
terminus of the receptor (Adler et al., 1992).
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Bef&Ptor Structure
Comparisons of sequences and functions of the various members of the steroid
receptor superfamily demonstrate a common basic structure for steroid receptors (for
rev. see Evans, 1988; see Figure 8). The trans-activation domain (region A/B) lies
closest to the amino-terminus of the receptor protein. This domain is highly variable
among the receptors and is responsible for the trans-activation function outlined
above. This region is also thought to play a role in gene recognition specificity
(Evans, 1988; Adler et al., 1992). The DNA-binding domain (region C) is a 66-68
amino acid region rich in cysteine residues which arrange themselves around zinc ions
forming the "zinc fingers" involved in binding to DNA (for rev. see Evans and
Hollenberg, 1988). The hinge region (region D) is involved in protein folding
following hormone-receptor coupling. The ligand-binding domain (region E) is a
220-250 amino acid region which forms a hydrophobic pocket for steroid binding.
This region is also the site of hsp90 binding. Surprisingly, neither the ligand-binding
domain nor the hormone is necessary for DNA binding. Rather, the ligand-binding
domain prevents the otherwise constitutive binding of the DNA binding domain to the
HRE, and ligand-receptor coupling relieves this inhibition (Godowski et al., 1987;
Hollenberg et al., 1987; Waterman et al., 1988). The region closest to the carboxy.:.
terminus of the receptor (F) is a highly variable region of unknown function.
The Androgen Rec<a>tor
The recent cloning and sequence analysis of androgen receptor (AR) cDNA
reveals a structure similar to other steroid receptors (Lubahn et al., 1988a; Chang et
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Figure 8. Structural and functional representation of steroid receptors. Receptors
are divided into six regions (A-F). The A/B region is located at the amino terminus
and is responsible for the trans-activation function of the receptor. The C region is a
highly conserved region responsible for DNA binding. The hinge region (D) is
involved in protein conformational changes. The E region forms a hydrophobic
pocket for ligand binding. The carboxy terminus of the protein (region F) is highly
variable and of unknown function (adapted from Evans, 1988).

al., 1988; for rev. see Janne et al., 1993). The deduced amino acid sequences of rat
and human AR reveal 902 and 919 amino acid proteins, respectively {Tan et al.,
1988; Lubahn et al., 1988b). The DNA-binding domain of the human AR shares
greatest homology with progesterone, mineralocorticoid, and glucocorticoid receptors
(Lubahn et al., 1988a) The amino terminal end (which is characteristically variable
among steroid receptors) shows little similarity to other receptor sequences (Lubahn et
al.,1988b). Furthermore, rat and human AR share complete amino acid sequence
identity in their DNA- and ligand-binding domains (Lubahn et al., 1988b; Tan et al.,
1988).

Aromatization of Testosterone
In the brain, testosterone can influence cellular function differentially
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depending on its intracellular fate (for rev. see McEwen et al., 1982). There are

threC alternative intracellular fates for testosterone (see Figure 9). Once testosterone
haS passed through the neuronal membrane, it can bind directly to AR or it can be
reduced by the intracellular enzyme, 5a-reductase, to DHT which also binds with
high affinity to AR. Alternatively, testosterone can be converted to 17/j-estradiol by
the intracellular aromatase enzyme (Weisz and Gibbs, 1974; Naftolin et al., 1975).
This 17/j-estradiol can then bind to estrogen receptors (ER) and will thus influence
cellular function in an alternate manner. Thus, the way in which testosterone will
affect neuronal function in specific brain regions depends on the presence or absence
of AR, ER, and the aromatase enzyme.
A recent study suggests that a large proportion of the aromatase-IR cells in the
quail brain do not contain immunoreactive ER (Balthazart et al. , 1991). In fact,
significant amounts of aromatase activity are found in synaptosomes purified by
differential centrifugation (Steimer, 1988; Schlinger and Callard, 1989). Also,
aromatase immunoreactivity is observed at the light microscopic level in fibers and
punctate structures (Balthazart et al., 1990) and at the electron microscopic level in
synaptic boutons (Naftolin et al., 1990). It has been hypothesized that aromatase
might produce estrogens which act at the synaptic level as neurohormones or
neuromodulators (Balthazart and Foidart, 1993). Although this is still quite
speculative, it is possible that aromatization of testosterone may occur in glia and in
neurons that do not contain ER. The generated 17/j-estradiol may then transfuse to
ER containing cells.
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Figure 9. The intracellular fates of testosterone. After diffusing through the cell
membrane, testosterone can either (1) bind the androgen receptor or (2) be reduced to
dihydrotestosterone and bind the androgen receptor. Alternatively, testosterone can
(3) be aromatized to 17/j-estradiol and bind the estrogen receptor.
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Distribution of Androgen and Estrogen Receptors
Steroid autoradiographic studies using 3H-DHT (Sar and Stumpf, 1977;
Sheridan 1978; Doherty and Sheridan, 1981; Wood et al., 1992) revealed androgen
target cells in the preoptic area, PVN, periventricular, ventromedial, and arcuate
nuclei of the hypothalamus in rat, mouse, and hamster. High DHT uptake was also
noted in the amygdala, lateral septum, BNST, and hippocampus. More recently,
immunohistochemistry and ISHH have revealed similar distributions of AR
immunoreactivity (Wood and Newman, 1993) and AR mRNA (Simerly et al., 1990).
It has been reported that the distribution of AR mRNA and CRH in the PVN do not

overlap (Simerly et al., 1990). However, this is contradicted by observations of AR
mRNA within this region (Handa, unpublished data).
The distributions of estrogen-concentrating cells, ER-IR cells, and ER mRNAexpressing cells have also been described previously (Pfaff and Keiner 1973; Loy et

al., 1988; Rhodes et al., 1982; Rhodes et al., 1981; Cintra et al., 1986; Don Carlos
et al., 1991; Pelletier et al., 1988; Simerley et al., 1990). The distribution of these
estrogen sensitive neurons significantly overlaps the distribution of AR containing
cells (Sar and Stumpf 1977; Sheridan, 1978; Doherty and Sheridan, 1981; Wood et

al., 1992; Wood and Newman 1993; Simerly et al., 1990). However, important
differences exist between the distribution of AR and ER. For example, ER
immunoreactivity and ER mRNA are abundant within the dorsal zone of the medial
parvocellular PVN where CRH neurons are localized (Don Carlos et al., 1991;
Simerly et al., 1990). Also, in the ventral zone of the medial parvocellular PVN

47
which contains many cells that project to autonomic regions of the brain stem and

spinal cord, AR mRNA- but not ER mRNA-containing cells have been observed
(Simerly et al., 1990). However, this contradicts earlier reports of estrogen
concentrating cells in this region (Rhodes et al., 1981).
In the rat the aromatase enzyme is concentrated in several brain regions that
contain ER such as the preoptic area, medial basal hypothalamus, lateral septum,
BNST, and amygdala (Naftolin et al., 1975; Selmanoff et al., 1977; Lauber et al.,
1993; Jakab et al., 1993). Thus, testosterone could influence cells in these areas
through it's aromatization to 17/3-estradiol and subsequent binding to ER.
Steroid hormones can influence the sensitivity of target cells to further
hormonal stimulation. A steroid hormone accomplishes this by regulating the
expression of genes encoding its own receptor, other steroid receptors, or the
aromatase enzyme. Androgen receptor and estrogen receptor provide examples of
homologous regulation of receptor expression (Saceda et al., 1988; Tan et al., 1988;
Ree et al., 1989; Shupnick et al., 1989; Berthois et al., 1990; Don Carlos et al.,
1990; Quarmby et al., 1990; Shan et al., 1990; Sanborn et al., 1991; Takeda et al.,
1991; Lauber et al., 1992; Lisciotto and Morrell 1993). Examples of heterologous
regulation of receptor expression include the regulation of androgen receptor and
progestin receptor by estrogen (Handa et al. , 1987; Handa and Rodriguez, 1991;
Blaustein et al., 1988; Don Carlos and Morrell, 1989). Furthermore, the induction of
aromatase activity by androgens represents a limiting factor in the activation of male
copulatory behavior and has been demonstrated in several species (Connolly et al. ,

48
1990; Hutchinson et al., 1990: Weaver and Baum, 1991; Harada et al., 1992; Fadem

et al., 1993; Harada et al., 1993; Resko et al., 1993; Connolly et al., 1994). Thus,
steroid hormones can influence the sensitivity of target cells by altering the
concentration of steroid receptors and the aromatase enzyme.

Implications and Hypothesis
In mammals, the biological reaction to anxiogenic stimuli involves wellcharacterized neuroendocrine, autonomic, and behavioral changes that serve to protect
the integrity of the organism. The neuroendocrine system responds with increases in
plasma ACTH, corticosterone, and prolactin. Autonomic outputs elicit very rapid and
specific changes including increases in blood pressure and heart rate. In the rat,
changes in behavior include an increase in freezing and a decrease in rearing.
Previous studies indicate that androgens affect the HPA axis. Gonadectomized
male rats have increased CORT and ACTH responses to physical or psychological
stressors as compared to intact animals (Handa et al., 1994). Furthermore, treatment
of castrates with testosterone or DHT restores the CORT and ACTH responses to
these stressful stimuli to that of intact rats. It is important to determine whether
circulating androgens influence other aspects of the stress response. Thus, our

hypothesis is that in the male rat, circulating androgens modulate the neuronal
circuitry responsible for mediating neuroendocrine and behavioral responses to
stressful stimuli. Dysfunction of the stress response is believed to lead to adjustment
disorders such as depression and panic disorder. These disorders occur much more
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often in females than in males (Weissman and Klerman, 1977; Katschnig and
Amering, 1990). Androgens may play a role in protecting a male from disfunction of
the stress response. Consequently, the following experiments were designed to
determine whether androgens influence CRH content, CRH-immunoreactivity, and
CRH mRNA levels in the PVN. It will be determined whether CRH-containing
neurons of the PVN contain androgen receptor, thus indicating whether androgens can
act within these cells to alter hypothalamic CRH levels. Finally, the effects of
androgens on neuroendocrine, autonomic, and behavioral responses to conditioned
stress will be examined.

CHAPI'ER ID

ANDROGENS INFLUENCE HYPOTHALAMIC CORTICOTROPINRELEASING HORMONE (CRH) AND CRH-IMMUNOREACTIVITY
FOLWWING GONADECTOMY

Summary

To characterize the effect of androgens on the hypothalamo-pituitary-adrenal
(HPA) axis we examined the regulation of corticotropin-releasing hormone (CRH)
following gonadectomy and hormone replacement. Three month-old, male Fischer
344 (F344) rats were gonadectomized (GDX) or sham gonadectomized (SHAM).
Control animals remained intact. Animals were sacrificed 1, 4, 7, 10, or 21 days
following surgery. GDX rats had significantly elevated (p<0.05) levels of
hypothalamic CRH 21 days after surgery compared to intact and sham-operated rats.
In a second study, three month-old male F344 rats were gonadectomized and treated
with the non-aromatizable androgen, dihydrotestosterone (DHT) using a Silastic
capsule containing crystalline DHT propionate subcutaneously implanted in each
animal's back. Control animals were gonadectomized and sham-treated (GDX) or left
intact (INT). Three weeks following GDX, CRH levels in the hypothalamus of GDX
50
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rats showed a significant increase (p<0.05) compared to intact animals. DHTtreatment at the time of gonadectomy prevented this increase. CRH or arginine
vasopressin (A VP) immunoreactivity was examined using immunocytochemistry. The
number of CRH-immunoreactive (IR) cells in the paraventricular nucleus (PVN) of
gonadectomized, DHT-treated animals was significantly decreased (p<0.05)
compared to GDX rats. No differences were seen between treatment groups in CRHIR cell numbers in the bed nucleus of the stria terminalis or the central amygdaloid
nucleus or in AVP-IR cell numbers in the PVN. These data demonstrate that long
term castration increases hypothalamic CRH content and CRH-IR cell numbers in the
PVN by removal of an androgen-dependent repression.

Introduction
The hypothalamo-pituitary-adrenal (HPA) axis is a principle component of an
animal's adaptive response to environmental perturbations. Neurons located in the
parvocellular region of the paraventricular nucleus (PVN) of the hypothalamus project
to the median eminence where they secrete a 41-amino acid peptide, corticotropinreleasing hormone (CRH), into the portal vasculature. Corticotropin-releasing
hormone then stimulates corticotrophs of the anterior pituitary to secrete
adrenocorticotropic hormone (ACTH) which in tum stimulates the secretion of
corticosterone (CORT) from the adrenal cortex.
Products of the HPA axis have been shown to inhibit reproductive function by
suppressing both gonadotropin secretion (Rivier and Vale, 1984; Rivier and Vale,
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19s5b; Rivier et al., 1986; Kamel and Kubajak, 1987) and reproductive behaviors
(Plas-Rose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986;
sirinathsinghji et al., 1986). Conversely, gonadal hormones are known to affect HPA
activity. Previous studies have demonstrated a significant sex difference in circulating
CORT levels and in the CORT response to stress with females having higher levels
than males (Kitay, 1961). The greater secretion in females is believed to be the result
of estrogen acting to enhance HPA activity (Kitay, 1963; Viau and Meaney, 1991a;
Burgess and Handa, 1992).
In contrast, in males androgens may inhibit HPA activity (Critchlow et al.,
1963; Gaskin and Kitay, 1971; Handa et al., 1994; Viau and Meaney, 1991b).
Previous studies have shown that prepuberal gonadectomy of the male rat and hamster
lead to enhanced levels of CORT which correlate with increases in ACTH bioactivity
(Critchlow et al., 1963; Gaskin and Kitay, 1971). Consistent with these findings, we
have shown that, following foot shock stress or exposure to a novel environment,
plasma CORT and ACTH levels are higher in gonadectomized male rats as compared
to intact animals. Furthermore, gonadectomized rats receiving replacement
testosterone or the non-aromatizable androgen, dihydrotestosterone (DHT), have poststress plasma CORT and ACTH levels similar to that seen in intact animals (Handa et

al., 1994). These data support the hypothesis that the sex difference in HPA activity
arises as a result of the circulating gonadal steroid environment.
Several possible mechanisms could explain androgen's inhibition of HPA
activity. Androgens could be inhibiting synthesis and secretion of hypothalamic CRH
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(or other corticotropin-releasing factors such as arginine vasopressin, AVP),
enhancing the negative feedback of the HP A axis, or decreasing anterior pituitary
sensitivity to CRH. The hypothesis that androgens influence the negative feedback
response is not supported because there are no differences in either concentration or
affinity of type I or type II CORT receptors in the hippocampus or hypothalamus in
intact versus castrated rats (Handa et al., 1994). Furthermore, anterior pituitary
responsiveness to CRH does not appear to be altered following gonadectomy of male
rats (Handa et al., 1994). The possibility remains that androgens could be
influencing hypothalamic CRH synthesis and secretion.
In order to determine whether androgens affect the HPA axis by inhibiting
hypothalamic CRH levels, we examined the effect of the non-aromatizable androgen,
DHT, on hypothalamic CRH content and CRH-immunoreactive (IR) cell numbers
within the PVN.

Materials and Methods
Animals
Three month old, male Fischer 344 rats (F344, Harlan/Sprague Dawley,
Indianapolis, IN) were maintained on a 12: 12 light: dark schedule with lights on at
0700h. Animals were housed in temperature controlled rooms. Food and water were
available ad libitum. For timecourse studies, animals were either bilaterally
gonadectomized (GDX) or received a sham operation (SHAM) under ether anesthesia.
Control animals remained intact (INT). Animals were sacrificed 1, 4, 7, 10,. or 21
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days after surgery between 0900 and llOOh. Animals were sacrificed by decapitation
immediately following removal from their home cage. Hypothalami were dissected
for evaluation of CRH content. To study the effects of androgen-replacement in
castrates, 3 month-old male F344 rats were bilaterally gonadectomized under ether
anesthesia. Gonadectomized animals received either hormone replacement using a 2.5
cm Silastic capsule (0.07" I.D., 0.125" 0.D.; Dow Coming, Midland, Ml)
containing crystalline dihydrotestosterone propionate (DHT) subcutaneously implanted
in each animal's back (GDX+DHT) or a sham incision (GDX). Control animals
were left intact (INT). Animals were sacrificed 21 days after surgery between 0900
and 1100 h. For measurement of hypothalamic CRH content, animals were sacrificed
by decapitation immediately following removal from their home cage. Trunk blood
was collected into tubes containing 300 µl 0.3 M ethylenediaminetetraacetic acid
(EDTA). Plasma was frozen (-80°C) until assayed for testosterone and DHT. For
immunocytochemical studies, animals were anesthetized with a lethal dose (0.13
mg/kg) of sodium pentabarbital and perfused through the ascending aorta with 4 %
buffered paraformaldehyde. Blood was taken by cardiac puncture just prior to
perfusion and added to tubes containing 300 µl 0.3 M EDTA. Animals were NOT
treated with colchicine prior to sacrifice because the resulting accumulation of CRH
could mask treatment effects.

CRH Radioimmunoassay (RIA)
Hypothalami were dissected according to the following landmarks: the .optic
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cbiaSm rostrally, the mammillary bodies caudally, the roof of the third ventricle
dorsally, the infundibulum ventrally, and the hypothalamic sulci laterally. Tissue was
homogenized in 1 ml 0.1 N HC1:2 N acetic acid (1: 1), boiled for 3 minutes, and
centrifuged at 2000 x g for 20 minutes. The supernatant was dessicated in a
Centrivap concentrator (Labconco, Kansas City, MO) and stored at -800 C until
assayed. CRH content was measured by RIA using anti-CRH serum (Peninsula
Laboratories, Belmont, CA) raised against synthetic CRH (human, rat).
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!-CRH

(NEN, Boston, MA) was used as the tracer. Protein concentration in the pellets

recovered following the 2000 x g centrifugation was determined by the method of
Lowry, et al. (1951). The ED50 was 30.65 pg/tube. The assay limit of detectability
was 11.8 pg/tube. The intra- and inter-assay coefficients of variance were 3.6% and
10.2%, respectively.

Immunocytochemistry
Brains were post-fixed overnight in 4% paraformaldehyde in borate buffer, and
20 µm-thick coronal sections were cut through the forebrain with a vibratome
(Technical Products Intl., St. Louis, MO). Every fourth section was used for
evaluation of CRH immunoreactivity. Adjacent sections were used for evaluation of
arginine vasopressin (AVP) immunoreactivity. The following primary antisera were
used in this study: anti-corticotropin-releasing hormone (lot #465) provided by the
late Dr. T.L. O'Donohue, and anti-arginine vasopressin (48 bleed 10) provided by
Dr. S.J. Watson (Univ. of Michigan, Ann Arbor). Free floating sections were
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incubated with antiserum diluted at either 1:2000 (CRH) or 1:10,000 (AVP) in 0.1 M
phosphate buffered saline with 0.25% Triton X-100 (Malinkrodt, Inc., Paris, KY) and
2% normal donkey serum for 18-24 hours at 4°C. Immunoreactivity was visualized
using a biotinylated secondary antibody, streptavidin-horseradish peroxidase, and
diaminobenzidine. Sections were mounted on gel-coated slides, and CRH-IR cells in
the PVN, bed nucleus of the stria terminalis (BNST), and central amygdaloid nucleus
(CeA), and AVP-IR cells in the PVN were counted without knowledge of treatment
group. Labelled cells were distinguished based on the discretion of the examiner.
The number of counted cells were multiplied by 4 (every fourth section was used) and
corrected for double-counting errors according to Abercrombie (1946).
As a control for antisera specificity, 1 ml of each diluted antiserum was
preincubated with 50 µg of its respective synthetic neuropeptide, and the sections
were processed as usual to determine whether any residual staining remained.
Although immunohistochemical staining was eliminated in these controls, it is possible
that these antisera may recognize unidentified neuropeptides containing similar amino
acid sequences. Thus, the neuropeptide immunoreactivity detected in this study is
more accurately described as neuropeptide-like immunoreactivity.

Steroid Radioimmunoassays
Plasma testosterone and DHT levels were evaluated by RIA using a mItestosterone kit (ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve ranged
from 5 to 500 pg/tube. Bound and free steroid were separated using a goat anti-rabbit
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gamma-globulin. The RIA sensitivity limit was 1.98 pg/tube. The intra-assay
coefficient of variance was 9.5%. All values were analyzed in one assay to avoid
inter-assay variation.
For plasma DHT determination, steroids were extracted from samples using
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals,
Inc.) using an isooctane-ethyl acetate system. DHT was eluted from the column with
5% ethyl acetate in isooctane. Recovery of DHT was 80%. Plasma DHT was
determined by RIA using a 3H-dihydrotestosterone RIA kit (ICN Biomedicals, Inc.).
The standard curve ranged from 10 to 500 pg/tube. Bound and free steroid were
separated using dextran-coated charcoal. The RIA sensitivity limit was 30.3 pg/tube.
The intra-assay coefficient of variance was 10.9%. All values were analyzed in one
assay to avoid inter-assay variation.

Statistics
Time course data were analyzed by two-way analysis of variance across
treatment and time (Winer, 1977). Data from DHT-replacement studies were
analyzed by one-way analysis of variance (Winer, 1977). Plasma DHT levels were
analyzed by a two-tailed t-test (Winer, 1977). A p value of

< 0.05 was considered

significant. Newman-Keuls' test was used for post hoc analysis.

58
Results
l1JrP91halamic CRH Levels
Radioimmunoassayable CRH content in the hypothalamus was significantly
increased (p<0.05) in GDX rats as compared to intact animals 21 days after surgery
(Figure 10). Sham gonadectomy had no effect on hypothalamic CRH content across
any time point examined. Hypothalmic CRH content in intact male F344 rats
averaged 1.6

+ 0.1

ng/hypothalamus. DHT administered continuously from the time

of gonadectomy prevented the effect of GDX 21 days after surgery (Figure 11).
Plasma testosterone and DHT levels are shown in Table 3. Gonadectomy reduced
circulating androgens, and hormone treatment increased DHT titers.

Immunocytochemistry
Corticotropin-releasing hormone-IR cell numbers were significantly greater
(p<0.05) in the PVN of GDX male rats as compared to GDX animals receiving
replacement DHT titers (Figure 12). When CRH-IR cell numbers in the PVN of
GDX and GDX

+ DHT rats were expressed as a percent of the intact cell count for

each immunocytochemical reaction, GDX rats had 198.1
GDX

+ 47.3%

and rats in the

+ DHT group had 63.2 + 12.0% of the CRH-IR cell numbers seen in intact

animals. No significant differences were seen in CRH-IR cell numbers in the BNST
or CeA between the treatment groups. Furthermore, no significant differences were
seen between treatment groups in AVP-IR cell numbers in the PVN. Representative
coronal sections demonstrating CRH-IR cells and AVP-IR cells in the PVN of intact,
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Figure 10. Hypothalamic CRH content in gonadectomized (GDX) and sham
gonadectomized (SHAM) male F344 rats 1, 4, 7, 10, or 21 days following surgery.
Values were determined by radioimmunoassay and expressed as a percent of the mean
hypothalamic CRH content of intact male rats (INT) run with each assay.
Hypothalamic CRH content of intact rats averaged 1.6 + 0.1 ng/hypothalamus.
*significant difference (p< .05) from intacts. #significant difference (p< .01) from
21-day shams. n=5-12/group. Each point represents the mean + the standard error
of the mean of values obtained from individual rats within each treatment group.
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Figure 11. Hypothalamic CRH content in intact (INT), gonadectomized (GDX), and
gonadectomized, dihydrotestosterone-treated (GDX + DHT) male F344 rats
determined by radioimmunoassay and expressed as pg CRH/mg protein. Animals
were gonadectomized 3 weeks prior to sacrifice. DHT was administered at the time
of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT propionate
implanted under the skin of each animal's back. *designates groups which are
significantly different (p<0.05) from intact animals. #designates groups which are
significantly different (p<0.05) from DHT-treated animals. n=5-6/group. Each bar
represents the mean + standard error of the mean of values obtained from individual
rats within each treatment group.
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Figure 12. CRH-IR and AVP-IR cell numbers in the paraventricular nucleus (PVN),
bed nucleus of the stria terminalis (BNST) and central nucleus of the amygdala (CeA)
of male F344 rats. Animals were either intact (INT) or bilaterally gonadectomized
under ether anesthesia. Half of the gonadectomized animals received either
dihydrotestosterone (GDX + DHT) or a sham operation (GDX). DHT was
administered continuously for the duration of gonadectomy using a 2.5 cm Silastic
capsule containing crystalline DHT propionate subcutaneously implanted in each
animal's back. * GDX and GDX + DHT groups are significantly different at
p<0.05. n=5-8/group. Each bar represents the mean + standard error of the mean
of values obtained from individual rats within each treatment group.
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Figure 13. Bright-field photomicrographs showing CRH-immunoreactive cells
(A,B,C) and AVP-immunoreactive cells (D) within the paraventricular nucleus of
intact (A), gonadectomized (B,D), and gonadectomized, dihydrotestosterone- (DHT)
treated (C) male F344 rats. Animals were gonadectomized 3 weeks prior to sacrifice.
DHT was administered continuously from the time of gonadectomy using a 2.5 cm
Silastic capsule containing crystalline DHT propionate subcutaneously implanted in
each animal's nape. The third ventricle is on the right. Bar = 100 µm.
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TABLE 3.

Plasma testosterone and dihydrotestosterone (DHT) levels in intact,

gonadectomized, and gonadectomized, DHT-treated male F344 rats determined by
radioimmunoassay. a,b
Testosterone (n)d,e

Ireatment"

1.267

INT

8

.167 (10)

ND (9)

GDX
GDX

+

+ DHT

DHT (n)d,e

.255

+ .065

(7)

ND (5)
1.538

ND (9)

+

.123 (6)*

Animals were gonadectomized 3 weeks prior to sacrifice. DHT was administered at

the time of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT
propionate implanted under the skin of each animal's back.
bPlasma hormone levels were determined in animals used for both CRH
radioimmunoassay and immunocytochemistry.

cINT, intact; GDX, gonadectomized; GDX

+ DHT,

gonadectomized, DHT-treated

dvalues expressed in ng/ml
en, number of animals per group
ND designates values too low to detect. The limits of detectability were 0.040 ng/ml
for testosterone and 0.145 ng/ml for DHT.

* Plasma DHT levels of GDX
than in intact animals.

+ DHT animals were significantly (p < .01) higher
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GDX, and GDX

+ DHT rats are shown in Figure 13.

Discussion
These data demonstrate that long term castration increases hypothalamic CRH
concentration. This increase in CRH in the gonadectomized male rat correlates with
the increased CORT and ACTH responses to physical and psychological stressors
previously observed in the gonadectomized male rat (Handa et al., 1994; Viau and
Meaney, 199lb) and suggests that this pool of CRH is readily releasable. Although a
previous study suggested that prepuberal gonadectomy of male rats did not affect
hypothalamic content of corticotropin-releasing bioactivity (Coyne and Kitay, 1971),
our data are consistent with a more recent study showing increases in hypothalamic
CRH peptide levels following long term castration (Almeida et al., 1992). Also
consistent with this study, we report here that greater than ten days is necessary to see
an effect of castration on hypothalamic CRH content. This effect is most probably
due to a release of inhibition by androgens since we have demonstrated that androgen
replacement restores hypothalamic CRH concentration to that of the intact animal.
This inhibition appears to be an androgen receptor-mediated event as the nonaromatizable androgen, DHT, was effective in suppressing castration-induced
increases in hypothalamic CRH concentration. Although it may appear that the levels
of plasma DHT in the DHT-treated castrates were supra-physiologic, it was our
intention to replace the total androgen (testosterone and DHT) lost due to the
gonadectomy. It should also be noted that our values for hypothalamic CRH .content
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are in the range of those previously reported

(Almeida et al., 1992).

We have demonstrated that CRH-IR cell numbers in the PVN of
gonadectomized male rats are greater than in gonadectomized rats receiving
replacement DHT titers. This suggests that in the absence of androgens CRH
synthesis or storage may be increased such that more cells can be detected
immunocytochemically. Alternatively, a subpopulation of cells within the PVN may
begin to synthesize CRH. It should be noted that the effect of androgens on CRH-IR
cell numbers in the PVN reported here was observed in animals that were not pretreated with colchicine. The accumulation of CRH that results from treatment with
colchicine could mask the effect of gonadal steroids on CRH immunoreactivity.
Whether androgen-induced changes in CRH-IR cell numbers and hypothalamic
CRH concentration occur as a result of changes in synthesis or degradation of CRH is
unknown. However, recent studies showing that CRH mRNA levels in the PVN are
not altered by short- or long-term castration (Almeida et al., 1992) suggest that CRH
synthesis may not be responsible for the increases in CRH content and CRH-IR cell
numbers observed in the present study.
In the brain, testosterone can act as either an androgen or an estrogen
depending upon its intracellular fate (for rev. see McEwen and Parsons, 1982). After
testosterone has passed through the neuronal membrane, it can bind directly to
androgen receptor or it can be reduced by the intracellular enzyme, 5a-reductase, to
DHT which also binds with high affinity to androgen receptor. Alternatively, if the
aromatase enzyme is present within the cell, testosterone can be converted to 17{3-
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estradiol (Weisz and Gibbs, 1974; Naftolin et al., 1975). This 17/j-estradiol can then
bind to estrogen receptors and will thus influence cellular function in an alternate
manner. The effect of androgens on hypothalamic CRH concentration and CRH-IR
cell numbers in the PVN appears to be an androgen receptor-mediated phenomenon as
the non-aromatizable androgen, DHT, was effective in reversing the effects of
castration. It is uncertain, however, whether androgens are acting directly on CRH
containing neurons in the PVN. Although both [3H]-DHT uptake (Sar and Stumpf,
1977) and androgen receptor mRNA (Simerly et al., 1990) have been detected in the
PVN, androgen receptor mRNA may not be localized in the parvocellular region of
the PVN where CRH containing neurons are found (Simerly et al., 1990).
Consequently, androgens may exert an effect on the PVN transsynaptically as
androgen receptor (Sar and Stumpf, 1977; Sheridan, 1979; Randa et al., 1987) and
androgen receptor mRNA (Simerly et al., 1990) are found within brain regions which
project (directly or indirectly) to the PVN such as the BNST (Swanson and Cowan,
1979; Silverman et al., 1981) and hippocampus (for rev. see Jacobson and Sapolsky,
1991). Furthermore, the effect of androgens on CRH-IR cell numbers appears to be
region-specific as no differences were seen among the treatment groups in either the
BNST or the CeA. This region-specificity of androgen action might better be
explained by a transsynaptic mechanism such as that hypothesized for steroidal
regulation of gonadotropin-releasing hormone (Petraglia et al., 1984; Bhanot and
Wilkinson, 1985; Gabriel et al., 1986; Wehrenberg et al., 1989; Kalra et al., 1990;
Sahu et al., 1990; Huang and Harlan, 1993).
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Arginine vasopressin (AVP) is present in both intra- and extrahypothalamic

siteS (Buijs, 1978). AVP has been colocalized with CRH in hypothalamic neurons
and potentiates the effect of CRH on ACTH secretion (Gillies et al., 1982; Antoni et

al., 1983; Rivier et al., 1984b; Sawchenko et al., 1984; Roth et al., 1982). The
density of AVP fibers originating in the BNST (DeVries and Buijs, 1983) and
innervating the lateral septum and lateral habenular nucleus is higher in males than in
females (DeVries et al., 1981). Furthermore, this sex difference is dependent on the
neonatal presence of testosterone (DeVries et al., 1983). In the adult animal,
androgens appear to maintain this sex difference since gonadectomy of male rats leads
to a disappearance of AVP-IR cell bodies in the BNST (DeVries et al., 1985; Miller

et al., 1992) and medial amygdala without affecting AVP-IR cell bodies in the PVN
(DeVries et al., 1985). Our studies also demonstrate that AVP-IR cell numbers in the
PVN were not influenced by the androgen status of the animal. While it is clear that
androgens can regulate AVP expression in some brain regions, changes in the AVP
system would not explain changes noted in the CORT and ACTH response to stress
noted in the castrated male rat (Handa et al., 1994; Viau and Meaney, 1991b).
In summary, the results of the present study demonstrate that castration
increases and androgens decrease hypothalamic CRH content and CRH-IR cell
numbers in the PVN. These parameters can be influenced by synthesis in the soma,
secretion from the terminals, and degradation of the neuropeptide. It is unknown at
this point which of these factors is altered by androgens. Additionally, while our data
indicate that androgen's influence on the HPA axis occurs, at least in part, at the level

69
of the hypothalamus, it should not be inferred that androgens act directly on the
hypothalamus. The PVN is a highly integrated and regulated cell group (for rev. see
Swanson and Sawchenko, 1983), and many possible target sites exist at which gonadal
steroids could act to ultimately regulate CRH cells within the PVN. There may exist
a complex pathway by which the circulating gonadal hormone milieu influences

adaptive physiological responses to environmental perturbations. It is clear that an
extensive interrelationship exists between the HPA and the hypothalamo-pituitarygonadal axes.

CHAYfER IV
CIRCULATING ANDROGENS DO NOT ALTER
CORTICOTROPIN-RELEASING HORMONE mRNA LEVELS IN THE
PARAVENTRICULAR NUCLEUS OF THE HYPOTHALAMUS

Summary
Previous studies demonstrate that long term castration increases hypothalamic
corticotropin-releasing hormone (CRH) content and CRH immunoreactivity in the
paraventricular nucleus of the hypothalamus (PVN) of male rats by removal of an
androgen-dependent repression. To characterize the effect of androgens on
hypothalamic CRH, we examined the effect of gonadectomy and androgen treatment
on CRH mRNA levels in the PVN of male rats. Three month-old, male Fischer 344
(F344) rats were bilaterally gonadectomized under ether anesthesia. Gonadectomized
animals received either the non-aromatizable androgen, dihydrotestosterone (DHT),
using a Silastic capsule containing crystalline DHT propionate subcutaneously
implanted in each animal's back (GDX+DHT) or a sham incision (GDX). Control
animals remained intact. For positive controls, male rats were adrenalectomized
(ADX) and sacrificed seven days after surgery. Corticotropin-releasing hormone
mRNA was examined by in situ hybridization histochemistry using a

35

S-labelled

oligonucleotide probe complementary to nucleotides 496-543 of rat CRH mRNA.
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.Arginine vasopressin (AVP) mRNA was similarly evaluated using a

35

S-labelled

oligonucleotide probe complementary to nucleotides 286-315 of prepro-AVP mRNA.
image analysis of hybridization density in the PVN showed no significant differences
in CRH mRNA or AVP mRNA between intact, GDX, and GDX + DHT animals
sacrificed 3 weeks after surgery. Similarly, the numbers of CRH mRNA-labelled
cells in the dorsal medial parvocellular, dorsal parvocellular, and ventral medial
parvocellular subdivisions of the PVN and the numbers of AVP mRNA-labelled cells
in magnocellular and parvocellular subdivisions of the PVN were not altered 3 weeks
after gonadectomy. In addition, there were no significant differences in CRH mRNA
hybridization in the PVN or in the numbers of CRH mRNA-labelled parvocellular
neurons among intact, GDX, and GDX, DHT-treated rats sacrificed 10 days after
surgery. These data suggest that changes in hypothalamic CRH content and CRH
immunoreactivity in the PVN after gonadectomy cannot be explained by changes in
CRH gene expression.

Introduction
Activation of the hypothalamo-pituitary adrenal (HPA) axis is a major
component of an organism's adaptive biological reaction to stressful stimuli. In
response to stress, neurosecretory cells in the parvocellular portion of the
paraventricular nucleus of the hypothalamus (PVN) synthesize and secrete
corticotropin-releasing hormone (CRH) into the hypohysial portal vasculature. CRH
serves as the major physiological stimulus promoting the secretion of
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adfenoeorticotropic hormone (ACTH) from the anterior pituitary. ACTH
subsequently causes the adrenal cortex to secrete corticosterone (CORT) into the
peripheral circulation. During stress, corticosterone influences several physiological
parameters including glucose mobilization, inflammation, and water resorption.
The interactions that take place between the HPA axis and the hypothalamopituitary-gonadal axis have been widely studied. Hypothalamo-pituitary-adrenal axis
hormones inhibit gonadotropin secretion and reproductive behavior (Rivier and Vale,
1984; Rivier and Vale, 1985b; Rivier et al., 1986; Kamel and Kubajak, 1987; PlasRose and Aron, 1981; Sirinathsinghji et al., 1983; Armstrong, 1986; Sirinathsinghji

et al., 1986). Conversely, gonadal hormones affect HPA activity. In rats, females
have higher circulating CORT levels and higher CORT responses to stress than males
(Kitay, 1961). Estrogen contributes to this sex difference by increasing HPA activity
(Kitay, 1963; Viau and Meaney, 1991a; Burgess and Handa, 1992). In contrast,
circulating androgens may inhibit HPA activity (Critchlow et al., 1963; Gaskin and
Kitay, 1971; Handa et al., 1994).
Circulating androgens appear to regulate the HPA axis, at least in part, at the
level of the hypothalamus. Previous studies have demonstrated that hypothalamic
CRH content is increased following gonadectomy of male rats (Bingaman et al. ,
1994). In addition, treatment of gonadectomized rats with dihydrotestosterone (DHT)
normalizes hypothalamic CRH content to that of intact animals. This is consistent
with studies which indicate that the ACTH and corticosterone responses to a physical
or psychological stressor are increased in gonadectomized male rats (Handa et al. ,
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1994; Viau and Meaney, 1991b).
Several mechanisms could explain the regulation of hypothalamic CRH by
androgens. Possibilities include an increased synthesis or half-life of CRH or a
decrease in axoplasmic transport and/or secretion following gonadectomy. This
experiment was performed to determine whether the influence of androgens on CRH
content and CRH immunoreactivity in the hypothalamus is a consequence of changes

in CRH gene expression. Corticotropin-releasing hormone mRNA levels in the PVN
of intact, gonadectomized, and gonadectomized, DHT-treated male rats were
evaluated using in situ hybridization histochemistry (ISHH). Arginine vasopressin
(A VP) mRNA levels in the PVN of these animals were similarly evaluated due to
AVP's role as a corticotropin-releasing factor.
Changes in CRH content may reflect concurrent changes in CRH mRNA.
Alternatively, in the castrate CRH synthesis may increase briefly and then return to
steady state once the larger CRH pool is established. If the latter case is true, the
transient increase in mRNA levels would be expected to precede changes in protein
content. Since hypothalamic CRH content begins to increase 10 days after
gonadectomy (Bingaman et al., 1994) with a significant increase by 21 days after
castration CRH mRNA levels were evaluated at 10 or 21 days following surgery.

Materials and Methods
Animals and Surgezy
Three month-old, male Fischer 344 rats (F344, Harlan/Sprague Dawley,
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Indianapolis, IN) were maintained on a 12: 12 light:dark schedule with lights on at
07()()h. Animals were housed in temperature controlled rooms. Food and water were
available ad libitum. Rats were bilaterally gonaclectomized under ether anesthesia.
Gonadectomized animals received either hormone replacement using a 2.5 cm Silastic
capsule (0.07" I.D., 0.125" O.D.; Dow Coming, Midland, MI) containing crystalline
DHT propionate subcutaneously implanted in each animal's back (GDX+DHT) or a
sham incision (GDX). Control animals were left intact (INT). Animals were
sacrificed either 10 or 21 days after surgery between 0900 and 1100 h. For positive
controls, three month-old male F344 rats were adrenalectomized under ether
anesthesia (ADX) and sacrificed seven days after surgery. All animals were
sacrificed by decapitation immediately following removal from their home cage.
Trunk blood was collected into tubes containing 300 µl 0.3 M
ethylenediaminetetraacetic acid (EDTA). Plasma was frozen (-80°C) until assayed for
testosterone and DHT.

Tissue Pre.paration
Brains were immediately removed, blocked, and frozen in isopentane (-20°C)
for 30 seconds and then placed on dry ice. Brains were stored at -800C until 18 µmthick frontal sections were cut on a cryostat. Sections were cut to include the PVN.
Sections were stored dessicated and frozen (-80°C) until use.
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~on

of Labelled Probes

Oligonucleotide probes complementary to nucleotides 496-543 of rat CRH
mRNA and nucleotides 286-315 of prepro-AVP mRNA were radiolabelled by poly-A
tailing in the presence of 35S-ATP (NEN; Boston, MA) using terminal
deoxynucleotidyl transferase (Boehringer Mannheim; Indianapolis, IN). The specific
activity of the CRH oligonucleotide probe was approximately 3.20x1018 dpm/mol.
The specific activity of the AVP oligonucleotide probe was approximately 3.43xl018
dpm/mol.

In Situ Hybridization
Every fourth section was used for evaluation of CRH mRNA levels. Sections
were processed for ISHH using the

35

S-labelled oligonucleotide probe complementary

to nucleotides 496-543 of rat CRH mRNA. Adjacent sections from rats treated for 21

days were analyzed using the

35

S-labelled oligonucleotide probe complementary to

nucleotides 286-315 of prepro-AVP mRNA. Sections were warmed to room
temperature, fixed in 4% formaldehyde, acetylated with 0.25% acetic anhydride in

O. lM triethanolamine/0.9% NaCl before dehydrating and delipidating in ethanols and
chloroform, respectively, and subsequent air drying. Radiolabelled probe was added
at a concentration of approximately 1.5 x 106 cpm/slide in 100 µl of hybridization
buffer (600mM NaCl, lOmM Tris-HCl, 0.02 % Denhart's, 1 mM
ethylenediaminetetraacetic acid (EDTA), 0.1 mg/ml denatured Herring testis DNA,
0.5 mg/ml total yeast RNA, 0.05 mg/ml yeast tRNA, 10% dextran sulfate, 0.05%
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sadium thiosulfate, 50 mM DTI, 0.05% sodium dodecylsulfate (SDS), 50%
tormamide). Hybridization was performed overnight (16-20 hours) at 37°C.
Nonspecific binding was removed by washing in 2xSSC at room temperature (lxSSC

== o.15 M NaCl, 0.015 M sodium citrate, pH 8.0), 2xSSC/50% formamide at 40°C,
and lx SSC at room temperature. Following dehydration in ethanols and drying
slides were apposed to Hyperfilm (3-max (Amersham; Arlington Heights, IL).
Autoradiograms were analyzed by image analysis of hybridization density.
Hybridized regions of the PVN were outlined using NIH Image software. The
density within was measured by comparison to a standard curve created by a slide of

c standards (Amersham, Arlington Heights, IL) which were converted to their 35 S

14

equivalents expressed as dpm/mg protein. (14C standards are used rather than

35

S due

to the long half-life of 14C.) Next, sections were dipped in Kodak NTB-3 nuclear
emulsion and exposed in a light-tight box for 3 112 weeks (CRH) or 3 days (AVP).
Sections were then stained with cresyl violet and labelled cells were counted under
darkfield microscopy. A cresyl violet-stained nucleus surrounded by exposed silver
grains was considered to be a radiolabelled cell. CRH mRNA expressing cells were
counted in three separate areas of the PVN (dorsal medial parvocellular, ventral
medial parvocellular, and dorsal parvocellular) as described by Swanson and Simmons
(1989). These areas are those in which CRH neurons are concentrated and were
quantified separately so that changes in any one functional division would not be
masked by lack of changes in other regions. Similarly, cells radiolabelled with the
AVP mRNA probe were counted separating cells observed in the magnocellular and
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parvocellular subdivisions. Cell counts were corrected for double-counting errors
(Abercrombie, 1946) .

.steroid Radioimmunoassays

Plasma testosterone levels were evaluated by radioimmunoassay (RIA) using a
1251-testosterone kit (ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve
ranged from 5 to 500 pg/tube. Bound and free steroid were separated using a goat
anti-rabbit gamma-globulin. The RIA sensitivity limit was 1.98 pg/tube. The intraassay coefficient of variance was 9.5%. All values were analyzed in one assay to
avoid inter-assay variation.
For plasma DHT determination, steroids were extracted from samples using
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals,
Inc.) using an isooctane-ethyl acetate system. Dihydrotestosterone was eluted from
the column with 5 % ethyl acetate in isooctane. Recovery of DHT was evaluated by
adding a known amount of 3H-DHT to the plasma sample prior to placement on the
column. Recovery of DHT was 80 %. Plasma DHT was determined by RIA using a
3

H-dihydrotestosterone RIA kit (ICN Biomedicals, Inc.). The standard curve ranged

from 10 to 500 pg/tube. Bound and free steroid were separated using dextran-coated
charcoal. The RIA sensitivity limit was 30.3 pg/tube. The intra-assay coefficient of
variance was 10.9%. All values were analyzed in one assay to avoid inter-assay
variation.
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SlatistlCS
The data are represented as the group means and the standard errors of the

mean (S.E.M.). In situ hybridization histochemistry data were analyzed by one-way
analysis of variance, and Newman-Keuls' test was used for post hoc analysis (Winer,
1977). Plasma DHT levels were analyzed by a two-tailed t-test (Winer, 1977). A p
value of < 0. 05 was considered significant.

Results
Plasma testosterone and DHT concentrations are shown in Table 4.
Gonadectomy reduced circulating androgens, and hormone treatment increased DHT
titers. It may appear as though the levels of plasma DHT in the DHT-treated
castrates were supra-physiologic. However, it was our intention to replace the total
androgen (testosterone and DHT) lost due to gonadectomy.
Figure 14 shows the hybridization density of a

35

S-labelled oligonucleotide

probe for CRH mRNA in the PVN of INT, GDX, GDX + DHT, and ADX animals.
Hybridization of the 35S-labelled probe to CRH mRNA was significantly increased
(p < .05) in the PVN of adrenalectomized animals compared to INT animals.

However, there were no significant differences in hybridization density in the PVN
between INT, GDX, and GDX+DHT animals 21 days after surgery. Figure 15
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Table 4. Plasma testosterone and dihydrotestosterone (DHT} levels in intact,
gonadectomized, and gonadectomized, DHT-treated male F344 rats determined by
radioimmunoassay. a

Testosterone (n)C·d

0.65

INT

ND (11)

GDX
GDX

+ 0.14 (11)

+ DHT

ND (9)

DHT (n)C·d

0.24

+ 0.05 (7)

ND (9)

1.50

+ 0.16 (6)*

aAnimals were gonadectomized 10 days or 3 weeks prior to sacrifice. DHT was
administered at the time of gonadectomy using a 2.5 cm Silastic capsule containing
crystalline DHT propionate implanted under the skin of each animal's back.

bINT, intact; GDX, gonadectomized; GDX

+ DHT,

gonadectomized, DHT-treated

'Values expressed in ng/ml
dn, number of animals per group
ND designates values too low to detect. The limits of detectability were .040 ng/ml
for testosterone and 0.145 ng/ml for DHT.
*Plasma DHT levels of GDX
than in intact animals.

+ DHT animals were significantly (p< .01) higher
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Figure 14. Hybridization density of a 35 S-labelled oligonucleotide probe
complementary to nucleotides 496-543 of rat CRH mRNA in the paraventricular
nucleus (PVN) of male F344 rats. Animals were either intact {INT), were bilaterally
gonadectomized under ether anesthesia, or were adrenalectomized (ADX).
Gonadectomized animals received either DHT using a 2.5 cm Silastic capsule
subcutaneously implanted in each animal's back (GDX + DHT) or a sham operation
(GDX). GDX and GDX+DHT animals were sacrificed by decapitation 21 days after
surgery. ADX animals were sacrificed 7 days after surgery. * designates groups
which are significantly different from intact group (p < .05).
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Figure 15. Numbers of cells in the dorsal medial parvocellular (PVNmpd), dorsal
parvocellular (PVNdp), and ventral medial parvocellular (PVNmpv) subdivisions of the
hypothalamic paraventricular nucleus radiolabelled using a 35 S-labelled oligonucleotide
probe complementary to nucleotides 496-543 of rat CRH mRNA. Animals were
either intact (INT), were bilaterally gonadectomized under ether anesthesia, or were
adrenalectomized (ADX). Gonadectomized animals received either DHT using a 2.5
cm Silastic capsule subcutaneously implanted in each animal's back (GDX + DHT) or
a sham operation (GDX). GDX and GDX + DHT animals were sacrificed by
decapitation 21 days after surgery. ADX animals were sacrificed 7 days after
surgery. * designates groups which are significantly different from intact group
(p< .01). n=3-6.
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Figure 16. Darkfield photomicrographs demonstrating CRH mRNA hybridization
over the paraventricular nucleus of the hypothalamus of intact (A), gonadectomized
(B), and adrenalectomized (C) male rats. Animals were gonadectomized 3 weeks
prior to sacrifice. Adrenalectomized animals were sacrificed 7 days after surgery.
Bar= 100 µm.
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shows the number of cells positively labelled for CRH mRNA in three regions of the
PVN of INT, GDX, GDX+DHT, and ADX male rats. There were significantly
more (p< .01) CRH mRNA-labeled cells in the dorsal medial parvocellular
subdivision of the PVN (PVNmpd) in ADX animals compared to intact rats. However,
in the PVNmpd the numbers of CRH mRNA-labelled cells in INT, GDX,
andGDX + DHT animals were not significantly different. In addition, the numbers of
CRH mRNA-labelled cells in the dorsal parvocellular (PVNdp) and ventral medial
parvocellular (PVNmpv) subdivisions did not significantly differ among the treatment
groups. Photomicrographs of representative frontal sections demonstrating CRH
mRNA expressing cells in the PVN of INT, GDX, and ADX male rats are shown in
Figure 16.
The hybridization density of a

35

S-labelled oligonucleotide probe for AVP

mRNA in the PVN of INT, GDX, GDX + DHT, and ADX animals is shown in
Figure 17. There were no significant differences in hybridization density in the PVN
among the treatment groups. However, the area hybridized was significantly greater
(p< .05) in ADX animals compared to intact animals (INT, 1.03 + 0.07 mm 2 ; ADX,

1.88 + 0.27 mm 2). The numbers of cells positively labelled for AVP mRNA in the
magnocellular (PVNM) and parvocellular (PVNp) subdivisions of the PVN of INT,
GDX, GDX+DHT, and ADX male rats are shown in Figure 18. There were
significantly (p < .01) more radiolabelled cells in the parvocellular, but not the
magnocellular, subdivision of the PVN in ADX animals compared to INT animals.
However, there were no significant differences in numbers of radiolabelled cells
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Figure 17. Hybridization density of a 35S-labelled oligonucleotide probe
complementary to nucleotides 286-315 of prepro-AVP mRNA in the paraventricular
nucleus (PVN) of male F344 rats. Due to the short exposure time for sections
hybridized with the probe for prepro-AVP mRNA, a standard curve could not be
generated. Therefore, hybridization density was expressed in optical density (O.D.)
units. Animals were either intact (INT), bilaterally gonadectomized under ether
anesthesia, or adrenalectomized (ADX). Gonadectomized animals received DHT
using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back
(GDX +DHT) or a sham operation (GDX). GDX and GDX +DHT animals were
sacrificed by decapitation 21 days after surgery. Adrenalectomized animals were
sacrificed 7 days after surgery. It should be noted that the scale for 0.D. units runs
from 0 to a maximum of 1.0.
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Figure 18. Numbers of cells in magnocellular (PVNM) and parvocellular (PVNP)
subdivisions of the paraventricular nucleus of the hypothalamus radiolabelled using a
35
S-labelled oligonucleotide probe complimentary to nucleotides 286-315 of preproAVP mRNA. Male rats were either intact (INT), bilaterally gonadectomized under
ether anesthesia, or adrenalectomized (ADX). Gonadectomized animals received
DHT using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back
(GDX +DHT) or a sham operation (GDX). GDX and GDX +DHT animals were
sacrificed by decapitation 21 days after surgery. Adrenalectomized animals were
sacrificed 7 days after surgery. * designates groups which are significantly different
from intacts (p< .01). n=3-6.
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Figure 19. Darkfield photomicrographs demonstrating AVP mRNA hybridization
over the paraventricular nucleus of the hypothalamus of intact (A), gonadectomized
{B), and adrenalectomized (C) male rats. Animals were gonadectomized 3 weeks
prior to sacrifice. Adrenalectomized animals were sacrificed 7 days after surgery.
Bar= 100 µm.
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Figure 20. Hybridization density of a 35S-labelled oligonucleotide probe
complementary to nucleotides 496-543 of rat CRH mRNA in the paraventricular
nucleus (PVN) of male F344 rats. Animals were either intact (INT) or were
bilaterally gonadectomized under ether anesthesia. Gonadectomized animals received
DHT using a 2.5 cm Silastic capsule subcutaneously implanted in each animal's back
(GDX+DHT 1()d) or a sham operation (GDX 1()d). Animals were sacrificed by.
decapitation 10 days after surgery. n=6.
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Figure 21. Numbers of cells in the dorsal medial parvocellular (PVNmpd), dorsal
parvocellular (PVNdp), and ventral medial parvocellular (PVNmpv) subdivisions of the
hypothalamic paraventricular nucleus radiolabelled using a 35 S-labeled oligonucleotide
probe complementary to nucleotides 496-543 of rat CRH mRNA. Animals were
either intact (INT) or were bilaterally gonadectomized under ether anesthesia.
Gonadectomized animals received DHT using a 2.5 cm Silastic capsule
subcutaneously implanted in each animal's back (GDX +DHT) or a sham operation
(GDX). Animals were sacrificed by decapitation 10 days after surgery. n=4-6.
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among INT, GDX, and GDX + DHT rats. Photomicrographs of representative frontal
sections showing AVP mRNA expressing cells in the PVN of INT, GDX, and ADX
male rats are shown in Figure 19.
Figure 20 shows the hybridization density of the 35 S-labelled oligonucleotide
probe for CRH mRNA in the PVN of intact male rats (INT), male rats that have been
castrated for 10 days (GDX 10d), and rats that have been castrated and DHT-treated for
10 days (GDX+DHT 10d). There were no significant differences in
hybridizationdensity among these treatment groups. The numbers of cells positively
labelled for CRH mRNA in three subdivisions of the PVN (PVNmpd' PVNdP' and
PVNmpv) of INT, GDX 10d, and GDX + DHT IOd are shown in Figure 21. The number
of radiolabelled cells did not significantly differ among the treatment groups in any of
the three subdivisions.

Discussion
Previous studies suggest that circulating androgens inhibit the activity of the
HPA axis (Critchlow et al., 1963; Gaskin and Kitay, 1971; Viau and Meaney, 1991b;
Handa et al., 1994). For example, the ACTH and corticosterone responses to
footshock or novel environment stress are increased in male rats three weeks after
gonadectomy (Handa et al., 1994). Furthermore, treatment of gonadectomized males
with testosterone or the non-aromatizable androgen, DHT, normalizes the ACTH and
corticosterone responses to these stressors. The regulation of the HPA axis by
circulating androgens appears to occur, at least in part, at the level of the
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byp<>thaiamus. Hypothalamic CRH content is increased three weeks after castration in
male rats (Bingaman, et al., 1994).
The results of the present study indicate that CRH mRNA levels and the
number of CRH mRNA expressing cells in parvocellular PVN neurons are not altered

three weeks after castration. This is consistent with a previous study which suggests
that 7 or 28 days of gonadectomy does not alter CRH mRNA in the PVN (Almeida et

al., 1992). Thus, the changes observed in hypothalamic CRH content and CRHimmunoreactive cell numbers in the PVN after gonadectomy of male rats (Bingaman

et al., 1994) cannot be explained by concurrent changes in CRH mRNA in the PVN.
Alternatively, androgens could be suppressing the translational efficiency or
decreasing the half-life of the CRH peptide.
In contrast, we observed approximately a 60% increase in CRH mRNA levels
in the PVN seven days after adrenalectomy. Furthermore, adrenalectomy resulted in
an increase in the number of CRH mRNA expressing cells in the PVNmpd· These
data are consistent with studies reporting similar increases in CRH mRNA in the PVN
following adrenalectomy (Young et al., 1986a; Kovacs and Mezey, 1987; Beyer et
al., 1988; Swanson and Simmons, 1989; Imaki et al., 1991). It has been reported
that while corticosterone may decrease CRH gene expression in the PVNmpd' high
levels of corticosterone increase CRH mRNA in the PVNdp and PVNmpv (Swanson
and Simmons, 1989). In the present study we did not observe a significant difference
in the number of CRH mRNA expressing cells in the PVNdp or the PVNmpv in
adrenalectomized animals compared to intact rats. It is possible that the levels of
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cireulating corticosterone in the intact rats are not sufficiently high to achieve a
significant difference compared to adrenalectomized animals.
The effect of gonadectomy and androgen treatment on AVP mRNA levels in
the PVN were evaluated due to AVP's role as a corticotropin-releasing factor. The
data indicate that AVP mRNA levels and the number of AVP mRNA expressing cells

are also not altered three weeks after gonadectomy. Adrenalectomized animals were
again used as a positive control. The number of AVP mRNA expressing cells was
significantly increased in parvocellular PVN neurons of adrenalectomized rats
compared to intact animals. These data are consistent with previous studies (Young et

al., 1986b; Swanson and Simmons, 1989).
It is not surprising that circulating androgens had no effect on AVP gene

expression. It was previously reported that gonadectomy of male rats did not lead to
changes in AVP immunoreactivity in the PVN (DeVries et al., 1985; Bingaman et

al., 1994). Although it is clear that androgens regulate AVP-immunoreactivity and
AVP mRNA levels in the bed nucleus of the stria terminalis and medial amygdala
(DeVries et al., 1985; Miller et al., 1992), androgens do not appear to influence AVP

gene expression in the PVN.
Previously, it was reported that hypothalamic CRH content begins to rise 10
days after gonadectomy of male rats (Bingaman et al. , 1994). It is possible that CRH
synthesis may increase briefly in the castrate and then return to steady state once the
larger CRH pool is established. If this were the case, this transient increase would be
expected to precede changes in protein content. However, in the present study CRH
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JDRNA levels in the PVN were not altered 10 days after gonadectomy. This suggests
that the increase in hypothalamic CRH content following gonadectomy (Bingaman et

al., 1994) is not the result of a transient increase in CRH gene expression. A small
increase in the number of CRH mRNA expressing cells was observed in the PVNmpd
10 days after gonadectomy. This increase was not, however, statistically significant.
Thus, it is possible that there is a transient increase in CRH gene expression and that
this change occurs in a small subset of cells such that the effect is masked using the
analysis techniques employed in this study. It is also possible that 10 days after
gonadectomy is not the optimum time point to observe such a transient change in
CRH gene expression.
In summary, the results of this study suggest that CRH and AVP mRNA levels
in the PVN are not affected by circulating androgens. Thus, previously reported
changes in hypothalamic CRH content and CRH-immunoreactive cell numbers in the
PVN after gonadectomy cannot be explained by changes in CRH gene expression. It
is possible that circulating gonadal androgens alter hypothalamic CRH content by
altering CRH translational efficiency or peptide half-life. In addition, it should be
noted that it is not known whether androgens act directly on the PVN to affect
changes in CRH content. There may exist a complex pathway by which circulating
androgens regulate CRH neurons and thus, the HPA axis.

CHAYfER V
LOCALIZATION OF ANDROGEN RECEYfOR-IMMUNOREACTIVITY
WITHIN PEPIIDERGIC NEURONS OF THE RAT BRAIN

Summary
This study tested for the presence of androgen receptor immunoreactivity in
somatostatin, galanin, vasopressin, corticotropin-releasing hormone, and oxytocin
neurons in the rat forebrain. The brains of adult male Sprague/Dawley rats were
fixed with 4 % paraformaldehyde. Androgen receptor was visualized in coronal
sections using nickel intensification of diaminobenzidine, and the neuropeptides were
identified using a brown diaminobenzidine reaction product. Androgen receptor was
localized to the nuclei of neurons in the septum, amygdala, cortex, hippocampus and
hypothalamus. The majority of somatostatin containing neurons in the periventricular
hypothalamic nucleus also contained androgen receptor. Androgen receptor was also
found within galanin expressing cells in the bed nucleus of the stria terminalis and in
the amygdala. Androgen receptor was not observed in corticotropin-releasing
hormone, vasopressin, or oxytocin neurons in any area examined. The data suggest
that androgens may be capable of directly regulating somatostatin expressing neurons
of the periventricular nucleus of the hypothalamus and galanin containing neurons of
the bed nucleus of the stria terminalis and amygdala.
95
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Introduction
The regulation of cellular processes by androgens requires the presence of the
androgen receptor (AR) which acts as a ligand-responsive transcription factor. The
distribution of AR in the brains of several species has been described previously
(Handa et al., 1987; Sar and Stumpf, 1975). In the rat, AR is localized throughout
many forebrain regions including the septum, amygdala, cortex, hippocampus, and
hypothalamus. This distribution overlaps that of many neuropeptide transmitters and
hormones.
Several recent studies have examined the regulation of neuropeptides by
androgens. Somatostatin (Gross, 1980) and somatostatin mRNA (Argente et al.,
1990; Werner et al., 1988) in hypothalamic neurons are increased by testosterone
providing one mechanism through which androgens may control growth hormone
secretory patterns. Vasopressin (AVP) immunoreactivity (DeVries et al., 1985;
Miller et al., 1992), AVP mRNA (Miller et al., 1992), and galanin mRNA (Miller et

al., 1993a) are decreased in the bed nucleus of the stria terminalis (BNST) by longterm castration. Recent evidence also suggests that androgens suppress corticotropinreleasing hormone (CRH) immunoreactivity in the hypothalamic paraventricular
nucleus (Almeida et al., 1992; Bingaman et al., 1994) thereby influencing the
hypothalamo-pituitary-adrenal response to stress. These neuropeptide systems provide
an opportunity to examine androgen receptor-mediated regulation of chemically
identified neurons.
It is currently unknown whether androgens are capable of directly regulating
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forebrain neuropeptide transmitters. In order for this to occur, AR must be expressed
within neuropeptide containing cells of the central nervous system, and an androgen
response element should be present upstream of the neuropeptide gene. The
following experiment tested for the presence of AR immunoreactivity within
somatostatin, galanin, AVP, CRH, and oxytocin neurons in the rat forebrain.

Materials and Methods
Six adult male Sprague/Dawley rats (250-275 g) were given a lethal dose of
sodium pentobarbital and perfused through the ascending aorta with 4 %
paraformaldehyde. Brains were removed and post-fixed overnight in
paraformaldehyde. 30 µm-thick coronal sections were cut through the diencephalon
on a vibratome (Technical Products Intl., St. Louis, MO). Androgen receptor
immunoreactivity was visualized using an immunoaffinity purified rabbit polyclonal
antibody to rat/human androgen receptor (Prins et al., 1991). This antibody was
generated using a synthetic peptide corresponding to amino acids 1-21 of AR and was
the generous gift of Dr. Gail S. Prins (Department of Obstetrics & Gynecology,
Univ. of Illinois College of Medicine, Chicago, IL). Free-floating sections were
incubated with antiserum diluted at 0.5 ug/ml in 0.1 M phosphate buffered saline
(PBS) with 0.25% Triton X-100 (Malinkrodt, Paris, KY) and 2% normal donkey
serum for 18-24 hours at 4°C. Sections were incubated with biotinylated donkey antirabbit gamma-globulin (1:250; Jackson Immunoresearch, West Grove, PA) and then
in streptavidin-horseradish peroxidase (Vector, Burlington, CA). Nickel ammonium
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sulfate (25 mg/ml) intensified diaminobenzidine (DAB) was used as the chromagen
yielding black-stained cell nuclei. Following the immunohistochemical reaction for
AR-IR cells, sections were washed in PBS with 0.25% Triton X-100 for 38-42 hours
at 4°C.
The following primary antisera were used for the immunohistochemical
detection of neuropeptides: anti-corticotropin-releasing hormone (lot #465) provided
by the late Dr. T.L. O'Donohue, anti-arginine vasopressin (48 bleed 10) and antioxytocin (45 bleed 10) provided by Dr. S.J. Watson (Univ. of Michigan, Ann Arbor),
anti-galanin obtained from Peninsula Labs (San Carlos, CA, RAS-7153N, lot#
006807), and anti-somatostatin obtained from Incstar (Stillwater, MN, lot# 853027).
After washing the sections stained for AR-IR, these sections were incubated with
antiserum diluted at either 1: 1000 (galanin and somatostatin), 1:2000 (CRH), or
1:10,000 (AVP and oxytocin) in O.lM PBS with .25% Triton X-100 and 2% normal
donkey serum for 18-24 hours at 4°C. Immunoreactivity was visualized using a
biotinylated secondary antibody, streptavidin-horseradish peroxidase, DAB complex as
described above except that nickel ammonium sulfate was not present. Sections were
mounted on gel-coated slides.
To verify specificity of AR antibody immunostaining, the AR antibody was
preincubated with either the peptide used to generate the AR antibody or a distant
peptide prior to exposure to the tissue. The peptide used to generate the antibody
(peptide 1-21) competed off specific signal. The distant peptide (peptide 462-478) had
no effect on AR-IR. As a control for neuropeptide antisera specificity, 1 ml of each
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diluted antiserum was preincubated with 50 µg of its respective synthetic
neuropeptide, and the sections were processed as usual to determine whether any
residual staining remained. Specific immunohistochemical staining was not observed
in these controls. However, it is still possible that these antisera may recognize

unidentified antigens containing similar amino acid sequences. Thus, the
immunoreactivity detected in this study is more accurately described as AR-like and
neuropeptide-like immunoreactivity.
Peptide-IR cells were identified by the presence of brown cytoplasmic
immunohistological staining. Cells were considered to be AR-IR if a dark-stained
nucleus was discernable. Neurons containing AR-IR and peptide-IR (i.e. doublelabelled cells) exhibited a dark-stained nucleus surrounded by a brown cytoplasm.
AR-, peptide-, and double-labelled cells were counted throughout nuclei in which
colocalization was observed. Every fourth section was sampled and used for
evaluation of AR-IR in conjunction with the immunoreactivity of a single peptide.

Results
The distribution of AR-IR was similar to the distribution of AR previously
described (Sar and Stumpf, 1975; Handa et al., 1987; Wood and Newman, 1993).
AR-IR was abundant in the lateral septum, BNST, medial preoptic area, ventromedial
and arcuate nuclei of the hypothalamus, CAl region of the hippocampus, amygdala,
and cortex. AR staining was localized predominantly in cell nuclei. The distribution
of somatostatin, galanin, AVP, CRH, and oxytocin overlapped that of AR in many
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forebrain regions examined.
AR was found within somatostatin containing neurons of the periventricular
nucleus of the hypothalamus adjacent to the third ventricle (figure 22 A,B). In the
periventricular nucleus, double-stained cells represented 78.7+6.4 % of somatostatinIR neurons and 54.6+9.8% of AR-IR neurons {n=3). A few somatostatin containing
cells in the paraventricular nucleus of the hypothalamus also expressed AR.
AR-IR was also found within galanin containing cells in the BNST (figure 22
C,D) and the medial and central amygdaloid nuclei. In the BNST double-stained cells
represented 39.0+4.9% of galanin-IR and 1.1 +0.4% of AR-IR neurons {n=3). In
the medial amygdala, 44.0 % of galanin expressing cells also expressed AR while
1.25 % of AR-IR cells also contained galanin {n=2). In the central nucleus of the
amygdala, double-stained cells represented 23 .1 % of galanin cells and 1. 3 % of AR-IR
neurons {n=2).
Nuclear staining was not observed in somatostatin- and galanin-IR cells in
areas that did not show AR-IR. For example, nuclear staining was not observed in
somatostatin-IR neurons of the caudate putamen. Similarly, brown cytoplasmic
staining was not seen in areas where AR-IR, but not somatostatin- or galanin-IR cells,
are found (e.g. the ventromedial hypothalamus).
AR was not found in CRH (figure 22 E,F), AVP, or oxytocin neurons in the
hypothalamus, septum, BNST, or amygdala.
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Figure 22. Brightfield photomicrographs showing localization of androgen receptor
immunoreactivity within somatostatin containing neurons in the periventricular nucleus
of the hypothalamus (A, B), localization of androgen receptor immunoreactivity
within galanin expressing neurons in the bed nucleus of the stria terminalis (C, D),
and the distribution of androgen receptor immunoreactivity and corticotropin-releasing
hormone (CRH) immunoreactivity in the paraventricular nucleus of the hypothalamus
(E, F). Androgen receptor immunoreactivity was visualized using nickel intensified
diaminobenzidine yielding a black reaction product within cell nuclei (open arrows).
Somatostatin (A,B), galanin (C,D), and CRH (E,F) immunoreactivity was visualized
as a brown diaminobenzidine reaction product present in the cell cytoplasm (solid
arrows). Examples of double-stained cells are indicated with an asterisk(*).
3V=third ventricle. Bar indicates either 500 µm (A,C), 250 µm (E), or 50 µm
(B,D,F).
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Discussion
These data demonstrate that AR is localized within somatostatin expressing
cells of the periventricular nucleus of the hypothalamus. Cells in this region project
to the median eminence where somatostatin acts as the major inhibitor of growth

hormone secretion from the anterior pituitary (Brazeau et al., 1973). Previous studies
have demonstrated a sex difference in the secretory patterns of growth hormone (for
rev. see Jansson et al., 1985). Growth hormone secretion is influenced by circulating
gonadal steroids such that both stimulatory (growth hormone-releasing hormone,
GHRH) and inhibitory (somatostatin) inputs to pituitary growth hormone secretion are
modulated by gonadal steroids (Gross, 1980; Werner et al., 1988; Chowen-Breed et

al., 1989; Ulloa-aguirre et al., 1990; Zeitler et al., 1990; DeGennaro et al., 1991;
Zorilla et al., 1991). Although steroid regulation of growth hormone secretion has
yet to be completely defined, it is clear that androgens increase somatostatin mRNA
in the periventricular nucleus (Argente et al., 1990; Werner et al., 1988) through an
androgen receptor-mediated processes (Argente et al., 1990). Our data suggest that
androgens may act within hypothalamic somatostatin expressing neurons to alter
somatostatin gene expression.
We have demonstrated that AR is localized with galanin in neurons in the
BNST and amygdala. This is consistent with a recent report that androgen regulates
galanin gene expression in the BNST (Miller et al., 1993a) and suggests that
androgens act within galanin cells of the BNST.

Although the function of galanin in

the BNST is unknown, the majority of AVP neurons in this region express galanin
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rnRNA (Miller et al., 1993b). It has been suggested that a potential role for galanin
in these neurons may involve the presynaptic modulation of co-released vasopressin

(Miller et al., 1993b). Interestingly, we report here that AR-IR was not localized

within AVP-IR neurons in any region examined. This contradicts a recent report that
AR immunoreactivity is localized within AVP cells of the BNST and MeA (Zhou et

al., 1994). However, the Zhou study as well as previous reports of androgen
regulation of AVP immunoreactivity (DeVries et al., 1985; Miller et al., 1992)
involved the use of colchicine to demonstrate AVP-IR in the BNST and medial
amygdala. In this study, we did not use colchicine and thus saw very few AVP-IR
cells in the BNST and medial amygdala. The possibility remains that the ARIR/galanin cells we observed in the BNST and medial amygdala may express AVP but
would only display AVP-IR upon prior treatment with colchicine.
Recent studies suggest that androgens play a role in the regulation of the
neuroendocrine stress response (Handa et al., 1994). Hypothalamic CRH content and
CRH-IR in the paraventricular nucleus are decreased by androgens (Bingaman et al.,
1994). However, the absence of AR in the CRH containing cells throughout the
paraventricular nucleus suggests that androgens influence CRH neurons via a
transsynaptic mechanism. The data also suggest that androgens do not influence the
hypothalamo-pituitary-adrenal response to stress through direct actions on oxytocin or
AVP cells of the paraventricular nucleus. AR-IR was not found within AVP or
oxytocin expressing neurons in any subregion of the parvocellular or magnocellular
paraventricular nucleus.
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In summary, we have used a dual immunohistochemical technique to determine
whether neuropeptide containing cells contain the intracellular machinery to be
directly regulated by androgens. Using this technique, AR-IR was found within
somatostatin expressing cells of the hypothalamic periventricular nucleus and galanin
expressing cells of the BNST and amygdala. Colocalization of AR-IR and AVP,
CRH, or oxytocin was not observed in neurons of the rat forebrain. In light of the
fact that colchicine was not used in this study, the possibility exists that AR-IR was
not observed in AVP, CRH, or oxytocin containing neurons because some cell groups
that express these peptides may not have been stained. This double
immunohistochemical staining technique is a valuable tool in characterizing AR
containing cells. However, the great majority of AR containing cells in many limbic
brain areas have yet to be characterized in terms of transmitter phenotype.

CHAYfER VI
DIFFERENTIAL EFFECTS OF CIRCULATING ANDROGEN ON
NEUROENDOCRINE AND BEHAVIORAL RESPONSES
TO CONDIDONAL STRESS

Summary
The purpose of this study was to examine the effect of circulating androgens
on neuroendocrine, autonomic, and behavioral responses to stress. In rats stress
produces increases in plasma ACTH, corticosterone, prolactin, and renin, increases in
defecation, and characteristic behavioral changes. Androgens may play an important
role in the expression of these responses. The effects of conditioned stress were
studied in male Sprague/Dawley rats that were gonadectomized with or without
dihydrotestosterone (DHT) treatment or received sham surgeries. Animals were
stressed three weeks after surgery. The ACTH response to conditioned stress was
significantly potentiated (p< .01) in gonadectomized males compared to shamoperated and gonadectomized, DHT-treated animals. In stressed rats, plasma
corticosterone levels were significantly higher (p < .05) in gonadectomized animals
compared to DHT-treated castrates. The prolactin response to stress was decreased

(p< .01) in gonadectomized males compared to sham and gonadectomized, DHTtreated rats. The stress-induced increases in plasma renin activity and concentration
106

107
were not altered by gonadectomy or DHT. Non-stressed DHT-treated castrates
exhibited more "fear-like" behavior (e.g., more freezing and less sniffing) compared
to non-stressed sham and gonadectomized animals. However, conditioned stress

produced the same behavioral effects in all treatment groups. The results demonstrate
that the ACTH/corticosterone, prolactin, and behavioral responses to a psychological
stressor are differentially regulated by circulating androgens.

Introduction
Aversive or anxiogenic stimuli cause biological changes that have been termed
the stress response. This so-called stress response is characterized by well
documented neuroendocrine, autonomic, and behavioral reactions that serve to
preserve the integrity of the animal. Almost all forms of stress produce increases in
plasma adrenocorticotropic hormone (ACTH), corticosterone, prolactin, and renin (for
rev. see Van de Kar et al., 1991). Enhanced release of corticosterone and ACTH
reflects activation of the hypothalamo-pituitary-adrenal axis. Prolactin release is
regarded as a reliable index of the stress response, although the physiological
significance of prolactin release during stress is unclear. Stress-induced release of
renin from the kidney indicates that the renin-angiotensin system is stimulated. The
renin-angiotensin system plays an essential role in the regulation of blood pressure
and electrolyte balance (Imagana et al., 1984; Churchill et al., 1978). In most
species anxiogenic stimuli cause increases in defecation suggesting altered autonomic
output to the gastrointestinal system (Miyata et al., 1992). Behavioral indicators of
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streSS in the rat include an increase in freezing and a decrease in rearing, grooming,
sniffing, and locomotor activities (e.g., Rittenhouse et al., 1992; Britton et al., 1982).
A limited number of studies have examined the effects of gonadal steroids on
the stress response. A sex difference in basal corticosterone titers and in the
corticosterone response to ether stress has been reported (Kitay, 1961). Females have
higher basal corticosterone levels and enhanced corticosterone responses to stress
compared to males. Several studies suggest that this sex difference arises, in part, as
a result of estrogen acting to enhance hypothalamo-pituitary-adrenal activity (Kitay,
1963; Viau and Meaney, 1991a; Burgess and Handa, 1992). Conversely, circulating
androgens appear to inhibit ACTH and corticosterone responses to stress.
Gonadectomized male rats exhibit enhanced corticosterone and ACTH responses to
foot shock and open field stressors (Handa et al., 1994). Treatment of
gonadectomized rats with testosterone or the non-aromatizable androgen,
dihydrotestosterone (DHT}, normalizes the ACTH and corticosterone responses to
these stressors. Furthermore, in male rats the magnitude of the corticosterone
response to immobilization is negatively correlated with the levels of circulating
testosterone (Viau and Meaney, 199lb).
As noted above, most studies investigating the effect of gonadal hormones on
the stress response have sampled only one or two parameters of the stress response.
In the following experiment we examined the effects of circulating androgens on
neuroendocrine, autonomic, and behavioral indices of stress. It is important to
determine whether androgens selectively or globally modulate the expression of
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various parameters of the stress response. The effects of conditioned stress were
examined in male rats that were gonadectomized or gonadectomized and treated with
dihydrotestosterone. We tested whether gonadal androgens alter the corticosterone
and ACTH responses to conditioned stress as has been shown to occur in response to
footshock and open field stressors (Handa et al. , 1994). The effect of androgens on
stress-induced increases in plasma prolactin, renin concentration, and renin activity
also were examined. In addition, this experiment examined the influence of
androgens on the stress-induced changes in defecation and several behavioral
parameters associated with fear or anxiety.

Materials and Methods
Animals
Male Sprague/Dawley rats (200-250 g) were purchased from Harlan
(Indianapolis, IN). Sprague/Dawley rats were used rather than Fischer 344 (F344)
rats due to the great amount of animal handling inherent to the conditioning
procedure. It is difficult to achieve very low baseline hormone levels in control
animals using the inbred F344 strain. Animals were housed, 2 per cage, in
temperature (22-24°C) and humidity (50-55 %) controlled rooms. Animals were kept
on a 12: 12 h light: dark cycle with lights on at 0700h. Food and water were available
ad libitum. All experimental protocols were approved by Loyola University Animal
Care and Use Committee, and were conducted according to the NIH Guide for the
Care and Use of Laboratory Animals.
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Animals were bilaterally gonadectomized under halothane anesthesia. One half
of the gonadectomized animals were administered dihydrotestosterone (DHT) via a
2.5 cm Silastic capsule containing crystalline DHT propionate subcutaneously
implanted in each animal's back (GDX

+ DHT).

The remainder of the

gonadectomized animals received a sham incision (GDX). Control animals received
the same surgeries except that the gonads were not removed and capsules were not
implanted in their backs (SHAM).

Conditioned Stress Paradigm
Training and testing were conducted in a rectangular chamber with a grid floor
composed of stainless steel rods (7.6 mm in diameter) spaced 12.7 mm apart. The
walls and ceilings of the apparatus were made of Plexiglas and illuminated by a 20watt fluorescent lamp. The chamber was located inside a sound-proof box equipped
with a one-way mirror so that the animal's behavior could be videotaped. Scrambled
current shock was delivered through the grid floor.
Rats were randomly assigned to treatment groups (control versus stress). Cage
mates received the same treatment. Cage mates were tested sequentially and at the
same time of day (between 10:00 and 13:30 h) on 4 consecutive days. All rats were
handled 2 minutes/day on each of 4 consecutive days prior to training. Training was
begun 18 days after surgery. On each of 4 consecutive days, the rats were
transported to the conditioning chamber in a transfer cage identical to their home
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cage. The rats remained for 5 minutes in the transfer cage prior to placement in the
conditioning chamber. For the first 3 days, the experimental (stressed) animals
received a 10 sec inescapable foot shock (0.8 mA) that was initiated ten minutes
following placement in the chamber. Control rats were treated identically except that
they were never shocked. The rats were then returned to their home cage. On the
fourth day, animals were placed in the test chamber for 10 minutes but did not
receive a foot shock. At the end of the 10 minutes, the rats were removed,
transported to an adjacent room and killed by decapitation. Trunk blood was
collected for hormone analysis into tubes containing 0.5 ml of 0.3 M EDTA, pH 7.4.
Plasma samples were stored at -7CJ'C until assayed for various hormones. On the
fourth day, the fecal boli in the test chamber were counted after the removal of each
animal. In addition, animals were video-recorded during their final 10-minute
interval in the test chamber. Later, videotapes were viewed, and the duration and
frequency of freezing, sniffing, grooming, rearing, and locomotor behaviors were
scored using a computer program developed by Dr. Andrew D. Levy in the
laboratory of Dr. Louis D. Van de Kar (Loyola University, Dept. of Pharmacol. and
Exp. Ther.).

Biochemical Determinations

Plasma conicosterone and ACTH assays were performed on unextracted
plasma samples according to standard laboratory procedures as previously described
in detail (Lorens and Van de Kar, 1987; Carnes et al., 1986). Corticosterone was
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assayed using antiserum from ICN Biomedicals, Inc. (Casa Mesa, CA). Data were
analyzed by the computer program RIA-AID (Robert Maciel Assoc., Arlington, MA).
The sensitivity was 0.01 ng/tube, and the intra-assay variance was 4.5%. For
measurement of this and all subsequent hormones all values were obtained in one
assay to avoid inter-assay variance. The ACTH antiserum was purchased from IgG
Corp. (Nashville, TN). The ACTH antibody recognizes amino acids 5-18. The
antibody does not recognize a-MSH, P-endorphin, P-lipotropin, ACTH 1-24 or
ACTH 1-16 amide. The ACTH for standards (1-39) was obtained from Calbiochem
and
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1-labelled ACTH was obtained from Incstar (Stillwater, MN). The sensitivity

of the ACTH assay was 0.25 pg/tube, and the intra-assay variance was 4.2 %.

Prolactin radioimmunoassay (RIA) was performed with reagents provided by
the NIADDK. Anti-rat prolactin serum S-9 was used at a dilution of 1:25,500 as
described previously (Van de Kar and Bethea, 1982). The standards were made from
the rat prolactin reference preparation NIADDK-rprl-RP-3. Anti-rabbit IgG
(Calbiochem, San Diego, CA) was used to separate the free from the bound tracer.
The sensitivity of the assay was 0.02 ng/tube, and the intra-assay variability was
4.8%.

Plasma renin activity was measured using a RIA for generated angiotensin I
(ANG I) as described previously (Richardson-Morton et al., 1989). For the assay of

plasma renin concentration, a saturating concentration of exogenous renin substrate
(angiotensinogen) was incubated with plasma renin to generate ANG I at maximal
velocity. Plasma renin substrate was obtained from rats that were nephrectomized
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and received a dexamethasone injection (0.2 mg/rat) 24 h before sacrifice. The
procedure was described previously in detail (Richardson-Morton et al., 1989). RIA
of ANG I was conducted with antiserum produced in our laboratory (RichardsonMorton et al., 1989). The dilution of antiserum was 1: 16,000. The RIA sensitivity
limit was 13.5 pg ANG I/tube. The intra-assay variability was 4.4%.
Plasma testosterone levels were evaluated by RIA using a
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I-testosterone kit

(ICN Biomedicals, Inc., Casa Mesa, CA). The standard curve ranged from 5 to 500
pg/tube. Bound and free steroid were separated using a goat anti-rabbit gammaglobulin. The RIA sensitivity limit was 43 pg/tube. The intra-assay coefficient of
variance was 5.1 %•
For plasma DHT determination, steroids were extracted from samples using
hexane:ethyl acetate (3:2) and separated on microcelite columns (ICN Biomedicals,
Inc.) using an isooctane-ethyl acetate system. DHT was eluted from the column with
5% ethyl acetate in isooctane. Recovery of DHT was 75.9

+

1.3%.

Plasma DHT

was determined by RIA using a 3H-dihydrotestosterone RIA kit (ICN Biomedicals,
Inc.). The standard curve ranged from 10 to 500 pg/tube. Bound and free steroid
were separated using dextran-coated charcoal. The RIA sensitivity limit was 49
pg/tube. The intra-assay coefficient of variance was 7 .5 %.

Statistics
The data are represented as the group means and the standard errors of the
mean (S.E.M.). Data were analyzed by two-way analysis of variance across the two
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treatments (androgen status x stress/control), and Newman-Keuls' test was used for
post hoc analysis (Winer, 1977) using a computer program (NWA STATPAK,
Portland, OR). Plasma testosterone and DHT levels were analyzed by a two-tailed ttest (Winer, 1977). A p value of < 0.05 was considered significant.

Results
Plasma testosterone and DHT concentrations are shown in Table 5.
Gonadectomy reduced circulating testosterone, and hormone treatment increased DHT
titers.
Plasma ACTH concentration was significantly elevated (p < .01) in all
conditioned stress groups compared to the corresponding non-stressed control groups
(Figure 23A). In GDX animals, the plasma ACTH levels following conditioned stress
were significantly greater (p < .01) than in stressed intact (i.e. sham) animals. The
ACTH response to conditioned stress in DHT-treated castrates did not differ from that
of sham animals. Corticosterone levels were increased in all conditioned stress
groups compared to non-stressed control groups (Figure 23B). The increases were
statistically significant (p < .01) in the GDX and sham groups. The statistical analysis
indicated that no significant surgery x stress interaction occurred (F2, 37 =2.05,
p<0.14). However, a post hoc Newman Keuls' test revealed that following
conditioned stress, plasma corticosterone levels were significantly increased (p< .05)
in GDX male rats as compared to DHT-treated castrates. There were no significant
differences in plasma ACTH and corticosterone among the treatment groups i11 non-
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Table 5.

Plasma testosterone and dihydrotestosterone (DHT) levels in sham,

gonadectomized, and gonadectomized, DHT-treated male Sprague/Dawley rats
determined by radioimmunoassay. • Animals were either conditioned stressed or were
non-stressed controls.

Testosterone (n)C·d

SHAM/CONTROL

1.0

+ 0.2 (6)

SHAM/STRESS

2.4

+ 0.3 {7)e*

0.36

+

0.49

.04 (8)

+

.05 (8)

GDX/CONTROL

ND (8)

0.45

+

.05 (8)

GDXI STRESS

ND (8)

0.43

+

.03 (7)

GDX

+ DHT/CONTROL

GDX

+ DHT/STRESS

ND (8)

0.95

+

.07 (8l#
0.97

ND (8)

+

.06 (8)f#

•Animals were gonadectomized 3 weeks prior to sacrifice. DHT was administered at
the time of gonadectomy using a 2.5 cm Silastic capsule containing crystalline DHT
propionate implanted under the skin of each animal's back.
bSHAM, sham-operated; GDX, gonadectomized; GDX

+ DHT,

gonadectomized,

DHT-treated; CONTROL, non-stressed control; STRESS, conditioned stressed
'Values expressed in ng/ ml

dn, number of animals per group
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eplasma testosterone levels of SHAM/STRESS animals may be significantly higher
than those of SHAM/CONTROL rats due to cross-reactivity of the testosterone
antibody with corticosterone.
tnie measured levels of plasma DHT may reflect cross-reactivity of the DHT
antibody with corticosterone. Also, the levels of plasma DHT measured in SHAM
and GDX animals were very near the limit of detectability and therefore may not be
reliable.
ND designates values too low to detect. The assay limits of detectability were 0.86
ng/ml for testosterone and 0.22 ng/ml for DHT.
* Plasma testosterone levels of SHAM/STRESS animals were significantly (p < .01)

different from SHAM/CONTROL rats.
#

Plasma DHT levels of GDX

+ DHT/CONTROL and GDX + DHT/STRESS

animals were significantly (p< .01) different from SHAM/CONTROL and
SHAM/STRESS animals.
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Figure 23. Effect of gonadectomy and androgen replacement on plasma ACTH (A)
and corticosterone (B) concentration in conditioned stress and non-stressed control
rats. Animals were either sham gonadectomized (SHAM), gonadectomized (GDX),
or gonadectomized, dihydrotestosterone-treated (GDX + DHT). The data represent
the mean + the standard error of the mean (S.E.M.) of 7-8 rats per group.
* designates groups which are significantly different from the corresponding nonstressed control group (p< .01). #designates groups which are significantly different
from sham stress and GDX +DHT stress groups (p < .01). @ designates groups
which are significantly different from the GDX + DHT stress (but not the sham stress)
group (p < .05).
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Figure 24. Effect of gonadectomy and androgen replacement on plasma prolactin
concentration in conditioned stress and non-stressed control rats. Animals were either
sham gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized,
dihydrotestosterone-treated (GDX +DHT). The data represent the mean + the
standard error of the mean (S.E.M.) of 7-8 rats per group. **designates groups
which are significantly different from the corresponding non-stressed control group
(p< .01). *designates groups which are significantly different from the
corresponding non-stressed control group (p < .05). # designates groups which are
significantly different from sham stress and GDX +DHT stress groups (p < .01).
@ designates groups which are significantly different from sham stress group .
(p< .05).
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stressed control animals.
Plasma prolactin concentrations were significantly increased (p< .01) in all
stress groups compared to non-stressed control groups (Figure 24). The magnitude of
the stress-induced increase in plasma prolactin concentration was significantly lower
(p< .01) in castrates than in sham-operated animals and DHT-treated castrates. The
plasma prolactin concentration following conditioned stress was significantly lower
(p< .05) in DHT-treated castrates compared to sham-treated animals.
Plasma renin activity and plasma renin concentration were significantly
increased (p < .05) in all conditioned stress groups compared to the corresponding
non-stressed control groups (Figure 25). Plasma renin activity and concentration were
not significantly different among the treatment groups in either stressed or unstressed
animals.
The number of fecal boli defecated in the chamber during the 10 minute
testing procedure was increased in all conditioned stress groups compared to nonstressed control groups (Figure 26). The increases were statistically significant
(p<.01) in the GDX and GDX+DHT groups. Conditioned stress GDX+DHT rats
defecated a significantly greater (p < .05) number of boli in the chamber compared to
stressed sham animals. No significant differences were seen between castrates and
DHT-treated castrates in either stressed rats or in non-stressed controls.
The duration of freezing behavior was significantly increased (p < 0.01) in all
conditioned stressed groups compared to non-stressed control groups (Figure 27).
Sniffing duration, grooming duration, rearing duration and frequency, and locomotor
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Figure 25. Effect of gonadectomy and androgen replacement on plasma renin
activity (A) and plasma renin concentration (B) in conditioned stress and non-stressed
control rats. Animals were either sham gonadectomized (SHAM), gonadectomized
(GDX), or gonadectomized, dihydrotestosterone-treated (GDX +DHT). The data
represent the mean + the standard error of the mean (S.E.M.) of 7-8 rats per group.
** designates groups which are significantly different from the corresponding nonstressed control group (p< .01). *designates groups which are significantly different
from the corresponding non-stressed controls (p< .05).
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Figure 26. Effect of gonadectomy and androgen replacement on defecation in
conditioned stress and non-stressed control rats. Animals were either sham
gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized,
dihydrotestosterone-treated (GDX + DHT). The data represent the mean + the
standard error of the mean (S.E.M.) of 7-8 rats per group. *designates groups
which are significantly different from the corresponding non-stressed control groups
(p< .01). #designates groups which are significantly different from the sham stress
group (p < .05).
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Figure 27. Effect of gonadectomy and androgen replacement on behavioral
responses to conditioned stress. The duration (A,B,C,D) and frequency (E,F) of
freezing (A), sniffing (B), grooming (C), rearing (D,E), and locomotion (F) were
scored from videotapes of conditioned stress and non-stressed control rats over a
period of 10 minutes in the testing chamber. Animals were either sham
gonadectomized (SHAM), gonadectomized (GDX), or gonadectomized,
dihydrotestosterone-treated (GDX +DHT). The data represent the mean + the
standard error of the mean (S.E.M.) of 7-8 rats per group. **designates groups
which are significantly different from the corresponding non-stressed control
(p<0.01). *designates groups which are significantly different from the
corresponding non-stressed control (p<0.05). #designates groups which are
significantly different from sham and GDX non-stressed controls (p < 0.01).
@ designates groups which are significantly different from sham non-stressed .controls
(p<0.05).
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frequency were significantly decreased (p<0.01) in all conditioned stress groups
compared to non-stressed controls. No differences were seen among the treatment
groups in animals exposed to conditioned stress. Non-stressed DHT-treated
castratesexhibited more freezing (p < 0. 01) and less sniffing (p < 0. 01), grooming
(p<0.05), rearing (p<0.01), and locomotor (p<0.01) activities compared to nonstressed sham and GDX animals.

Discussion
These results indicate that the ACTH and corticosterone responses to
conditioned stress are increased in castrated male rats. Furthermore, androgen
treatment normalizes these responses to conditioned stress. This suggests that
androgens tonically suppress ACTH and corticosterone responses to stress. The data
are consistent with previous studies which demonstrated that gonadectomy increases
the ACTH (Coyne and Kitay, 1971; Randa et al., 1994) and corticosterone (Randa et

al., 1994) responses of male rats to ether (Coyne and Kitay, 1971), footshock (Randa
et al., 1994) and open field (Randa et al., 1994) stressors. The hypothesis that
androgens inhibit hypothalamo-pituitary-adrenal responses to stress is further
supported by data showing that the magnitude of the corticosterone response to
immobilization is negatively correlated with plasma testosterone titers (Viau and
Meaney, 1991b). The post-stress plasma corticosterone levels in gonadectomized
male rats were significantly increased compared to DHT-treated castrates. Following
stress, plasma corticosterone levels in gonadectomized male rats were increased
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compared to sham-operated animals, but the effect was not statistically significant.
The level of plasma DHT in the DHT-treated castrates was significantly higher than
that of sham-operated male rats (Table 5). Thus, the androgen effect on post-stress
corticosterone levels could be more apparent in the DHT-treated castrates than in
sham-operated animals because of the dampening effect of DHT. It is also possible
that corticosterone levels are still rising and a maximum treatment effect has not yet
been reached.
Several possible mechanisms could explain the enhanced corticosterone and
ACTH responses to stress in the gonadectomized male. Androgens could alter the
negative feedback of the hypothalamo-pituitary-adrenal axis. However, castrated male
rats exhibit no changes in either concentration or affinity of glucocorticoid or
mineralocorticoid receptors in the hippocampus or hypothalamus (Handa et al., 1994).
Also, anterior pituitary sensitivity to CRH is not altered in gonadectomized male rats
(Handa et al., 1994). However, hypothalamic CRH content and CRH
immunoreactivity in the paraventricular nucleus of the hypothalamus are increased in
gonadectomized male rats (Bingaman et al., 1994). Dihydrotestosterone treatment of
castrates normalizes hypothalamic CRH. Androgens probably influence hypothalamic
CRH activity through a transsynaptic mechanism. This is suggested by data showing
that androgen receptor immunoreactivity is not located within CRH neurons of the
paraventricular nucleus (Bingaman et al., in press). However, androgen receptors are
abundant in adjacent regions of the hypothalamus, the limbic system, and the
brainstem (Handa et al., 1987). Many of these regions are known to provide direct
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input to the paraventricular nucleus (for rev. see Swanson and Sawchenko, 1983).
The effect of gonadectomy on the ACTH and corticosterone responses to
conditioned stress were quite robust. This is important in light of the fact that the
conditioning paradigm employed in this study involved exposure of the animal to
stress on 4 consecutive days. Previous studies used only an acute single exposure to a
stressor (Coyne and Kitay, 1971; Viau and Meaney, 1991b; Handa et al., 1994).
Thus, the robust effect of androgens observed on the fourth day of exposure to the
stressor suggests that the effect is functionally important.
The data indicate that plasma prolactin is dramatically increased in response to
conditioned stress. The rise in plasma prolactin that occurs in response to conditioned
stress is significantly attenuated in castrated male rats. This is not completely
surprising since gonadectomized male rats have decreased basal prolactin titers
compared to intact animals (Shin et al., 1974; McNeilly et al., 1980; Brar et al.,
1985). Furthermore, administration of testosterone to gonadectomized rats leads to an
increase in basal circulating prolactin (Shin et al., 1974; Brar et al., 1985; Kalra et

al., 1973; Weidenbach et al., 1980). In the current study, a small decrease in plasma
prolactin was observed in control, gonadectomized rats. This decrease was similar in
magnitude to that reported previously (Brar et al., 1985). Two-way anova showed a
significant effect of androgens on plasma prolactin. However, post-hoc NewmanKeuls' analysis did not detect the small change in basal plasma prolactin as
statistically significant due to the large changes observed in plasma prolactin following
stress.
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Pituitary prolactin secretion is under the control of both prolactin-releasing
factors and a prolactin-inhibiting factor. Many putative prolactin-releasing factors
have been identified, e.g. vasoactive intestinal polypeptide, thyrotropin-releasing
hormone, oxytocin, and angiotensin II (for review see Ben-Jonathon et al., 1989).
The major candidate for a prolactin-inhibiting factor is dopamine (Ben-Jonathon,
1985). Gonadectomized male rats have an altered episodic pattern of prolactin
secretion (Grosser and Robaire, 1988) and a decreased pituitary prolactin content
(Herbert et al., 1977). The pulsatile nature of prolactin secretion is thought to be
controlled by central mechanisms since the pulsatile plasma prolactin patterns are no
longer found following sectioning of the pituitary stalk (Wehrenberg and Perin,
1982). This suggests that circulating androgens influence the central mechanisms
controlling pituitary prolactin secretion. However, a pituitary site of androgen action
is still possible.
Another mechanism by which androgens could affect pituitary prolactin
secretion is through the aromatization of testosterone to estrogen. Castrated rats
treated with DHT exhibited higher stress-induced prolactin levels compared to
gonadectomized males. However, administration of DHT was not sufficient to restore
post-stress prolactin titers to that of stressed sham animals even though plasma DHT
levels were higher than in intact (i.e., sham-operated) animals. Intact animals have
circulating testosterone while DHT-treated castrates do not. Testosterone can either
bind to the androgen receptor, be reduced to DHT and bind to the androgen receptor,
or can be aromatized to

17~-estradiol

and bind to the estrogen receptor (for review
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see McEwen and Parsons,

1982). Since DHT cannot be aromatized to 17/j-estradiol,

this steroid acts only through the androgen receptor. Thus, our data are consistent
with the hypothesis that testosterone increases prolactin release, in part, through
aromatization to 17/j-estradiol. Estrogen treatment of male or female rats results in
anterior pituitary gland growth and hyperprolactinemia (Chen and Meites, 1970; Ajika

et al., 1972; De Lean et al., 1977; Elias and Weiner, 1987; Cronin et al., 1982;
Perez et al., 1986; Handa and Rodriguez, 1991). This is, in part, a result of
lactotroph hypertrophy and hyperplasia as a consequence of decreased hypothalamic
dopamine secretion (Elias and Weiner, 1987; Cronin et al., 1982; Perez et al., 1986).
There is evidence demonstrating a direct anterior pituitary site of action of estrogen
on prolactin secretion (Palka et al., 1966; Nicoll and Meites, 1964; Raymond et al.,
1978). However, the possibility that the hypothalamus is also an important site of
control of prolactin secretion by estrogens cannot be excluded (Kanematsu and
Sawyer, 1963; Ramirez and McCann, 1964; Ahren et al., 1971; Hokfelt and Fuxe,
1972). It also remains to be determined whether androgens and estrogens act
synergistically to influence anterior pituitary physiology.
It is of interest to speculate on the physiological significance of androgen's

effect on post-stress plasma prolactin levels. High levels of plasma prolactin may
enhance immune function (Spangelo et al., 1987; Cross et al., 1989; Dardenne et al.,
1989; Mukherjee et al., 1990). Thus, the increased prolactin levels observed
following stress may protect the organism from stress-induced immune suppression.
Following the exposure to stressful stimuli, circulating androgens maintain the
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secretion of prolactin and thereby, may indirectly influence the immune system.
Moreover, since corticosterone is immunosuppressive (for rev. see Cupps and Fauci,
1982), the increased plasma corticosterone response to stress in the castrate could
conspire with a decreased prolactin response to suppress immune function.
Plasma renin activity and plasma renin concentration were significantly
increased following conditioned stress in all treatment groups. This is consistent with
previous studies (Richardson-Morton et al., 1989, Van de Kar et al., 1984; Van de

Kar et al., 1985). Plasma renin activity and concentration were not altered by
gonadectomy in either stressed or control castrated animals. The secretion of renin
from the kidney following exposure to stressful stimuli is thought to be caused by
both sympathetic activation (for rev. see Reid et al. , 1986) and a blood-borne reninreleasing factor (Urban et al., 1992). The secretion of this hypothalamic factor is
thought to involve both serotonergic (acting via a 5-HT2 receptor) and
catecholaminergic inputs to the PVN (Van de Kar, 1991, Richardson-Morton et al.,
1990). Our results suggest that these systems are not altered by circulating
androgens.
Conditioned stress led to an increase in the number of fecal boli defecated in
the chamber during the 10 minute testing procedure. Circulating androgens do not
influence the defecation of stressed rats since no difference was observed between
gonadectomized males and DHT-treated castrates. Thus, the autonomic output
influencing gastrointestinal activity was not affected by altering circulating androgens.
As expected, conditioned stressed animals displayed a significant increase in
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the duration of freezing behavior and significant decreases in the duration of sniffing,
grooming, and rearing and the frequency of rearing and locomotor behaviors
compared to non-shocked controls. No differences were seen among the treatment
groups in animals exposed to conditioned stress. This is not altogether surprising
when one considers that the stressed animals display a maximum of stress-like
behaviors leaving little room for variation. For example, stressed rats exhibited
freezing for approximately 90% of the time they were within the chamber (Figure
27A). Treatment differences were, however, seen among the non-stressed controls.
Non-stressed DHT-treated castrates exhibited more freezing and less sniffing,
grooming, rearing, and locomotor activities compared to non-shocked intact and
gonadectomized animals. Since the control rats were placed in the chamber for four
consecutive days (without being shocked), they were exposed to a mild amount of
stress inherent to the procedure. This mild stress is evident in plasma corticosterone
levels when one compares home cage control rats with rats subjected to this procedure
(home cage

co~trols,

0.8

conditioned stress, 12.9

+ 0.2 µg/dL;

+ µg/Dl;

non-shocked controls, 3.0

+ 0.8 µg/Dl;

Van de Kar, unpublished data). Thus, DHT-

treated castrates exhibited more "fear-like" behavior in response to this mild stressor
compared to intact and castrated rats. Differences between DHT-treated castrates and
intact animals could be attributed to the higher levels of DHT in the DHT-treated
castrates (Table 5) and/or to the nonaromatizable nature of DHT.
In summary, the data suggest that circulating androgens are necessary for a
normal response to conditioned stress. Removal of circulating gonadal androgens
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enhances the ACTH and corticosterone responses and attenuates the plasma prolactin
response to conditioned stress. Also, androgens may potentiate the behavioral
response to stress. The absence of gonadal androgens does not influence plasma renin
activity and concentration or defecation following conditioned stress. Thus,
circulating androgens differentially modulate the neural systems responsible for
expression of various components of the stress response. One major implication of
this study shoud be emphasized. To date, most studies investigating the effect of
gonadal hormones on the stress response have sampled only one or two parameters of
the stress response. This study indicates that circulating andrognes differentially
influence various components of the stress response. Examination of only one aspect
of the stress response, such as ACTH and/or corticosterone, may be misleading.
Depending on the parameter measured, subjects may appear less stressed, more
stressed, or unaffected by a particular treatment. Thus, evaluating other
neuroendocrine as well as autonomic and behavioral reactions to experimental
challenge may be necessary to more accurately determine how an organism is reacting
to stress.

CHAYI'ER VII
GENERAL DISCUSSION

Summary
Circulating gonadal steroids have been demonstrated to influence the
hypothalamo-pituitary-adrenal (HPA) axis (Kitay, 1963; Critchlow et al., 1963;
Gaskin and Kitay, 1971; Coyne and Kitay, 1971; Viau and Meaney, 1991a; Viau and
Meaney, 1991b; Burgess and Randa, 1992; Randa et al., 1994). While estrogen
enhances RPA activity (Kitay, 1963; Viau and Meaney, 1991a; Burgess and Randa,
1992), circulating androgens may suppress activity of the RPA axis (Critchlow et al.,
1963; Gaskin and Kitay, 1971; Randa et al., 1994). The first experiment of this
dissertation tested the hypothesis that androgens influence the RPA axis by reducing
hypothalamic levels of CRH. It was observed that hypothalamic CRH content is
increased in the male rat 3 weeks after bilateral gonadectomy. Treatment of
gonadectomized male rats with the non-aromatizable androgen, dihydrotestosterone
(DHT), normalizes CRH content to that seen in intact animals. Greater than 10 days

of castration was necessary in order to observe a change in hypothalamic CRH
content. Furthermore, three weeks after surgery, gonadectomized male rats had
significantly more CRH-immunoreactive (IR) cell numbers in the paraventricular
nucleus of the hypothalamus (PVN) compared to ORT-treated castrates. Thus, these
131
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data indicate that the effect of androgens on the HPA axis occurs, at least in part, at

the level of the hypothalamus.
The second experiment was performed to determine whether the influence of
androgens on CRH content and CRH immunoreactivity in the hypothalamus are a
consequenc of changes in CRH gene expression. Corticotropin-releasing hormone
mRNA levels in the PVN of intact, gonadectomized, and gonadectomized, DHTtreated male rats were evaluated using in situ hybridization histochemistry.
Corticotropin-releasing hormone mRNA levels in the hypothalamic paraventricular
nucleus, however, were not altered 10 days or 3 weeks after gonadectomy. Thus,
changes in CRH peptide levels cannot be explained by concurrent changes in mRNA
levels or by a transient elevation in CRH mRNA preceding the alteration of peptide
content.
The third experiment tested the hypothesis that androgens regulate CRH by
acting directly within CRH expressing neurons of the PVN. The regulation of
cellular processes by androgens requires the presence of the androgen receptor (AR)
which acts as a ligand-responsive transcription factor. In order for androgens to
directly regulate hypothalamic CRH, AR must be expressed within CRH containing
neurons. Thus, this study tested for the presence of AR immunoreactivity within
CRH neurons of the PVN in male rats. The results of this experiment suggest that
CRH containing neurons of the PVN do not contain AR immunoreactivity. Thus, it
is likely that androgens influence CRH content via a transsynaptic mechanism.
The final study was designed to determine whether circulating

androgen~
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influence neuroendocrine, autonomic, and behavioral responses to a psychological
stressor. The effects of conditioned stress were examined in male rats that were
intact, gonadectomized, or gonadectomized and treated with DHT. Consistent with
previous studies (Coyne and Kitay, 1971; Handa et al., 1994), the ACTH and
corticosterone responses to conditioned stress were enhanced in gonadectomized male
rats. However, the prolactin response to conditioned stress was suppressed in rats
deprived of circulating gonadal androgens. Furthermore, DHT-treatment increased
the expression of stress-associated behaviors. Thus, circulating androgens

dijferen.tially influence neuroendocrine and behavioral responses to conditioned stress.
Circulating androgens may selectively modulate the neuronal circuitry responsible for
mediating various aspects of the stress response.

Possible Mechanisms of Androgen Action
The HPA Axis
Androgens suppress HPA activity via central mechanisms. The loss of
circulating gonadal androgens induces an increase in hypothalamic CRH content.
This increase may explain the enhanced ACTH and corticosterone responses to
physical and psychological stressors previously observed in the gonadectomized male
rat (Coyne and Kitay, 1971; Handa et al., 1994). Also, anterior pituitary sensitivity
to CRH is not altered in the gonadectomized male rat (Handa et al., 1994). Thus,
androgens may act on a central nervous system (CNS) site(s) to alter HPA activity.
Several mechanisms could explain the regulation of hypothalamic CRH by
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androgens. Possibilities include an increased synthesis or half-life of CRH or a
decrease in axoplasmic transport and/or secretion following gonadectomy. The
possibility that axoplasmic transport and secretion of CRH are decreased following
castration can be excluded due to the fact that the ACTH and corticosterone responses
to stress are increased in the gonadectomized male rat (Coyne and Kitay, 1971;
Handa et al., 1994). The possibility remains that synthesis in the soma or
degradation of the peptide can be influenced by circulating androgens. Circulating
androgens could decrease CRH peptide half-life or reduce the translational efficiency
of CRH in parvocellular PVN neurons.
In the second experiment, CRH mRNA levels in the PVN were not altered 10
days or 3 weeks after gonadectomy. However, it is possible that changes in
hypothalamic CRH content observed after gonadectomy are the result of an alteration
of CRH gene expression. This hypothetical change in CRH gene expression might
occur only in a small subset of cells and thus would be masked by a lack of change
elsewhere in the PVN. Also, 10 days and 3 weeks after gonadectomy may not be the
appropriate time to see such a change.
If the increase in CRH content after gonadectomy is the result of changes in

gene expression, one might observe this change by measuring CRH mRNA after a
stressor. During homeostasis, CRH is stored in median eminence terminals and is
secreted in relatively small amounts in response to a circadian pacemaker (Dallman et

al., 1977). The presence of a real or perceived threat to the organism causes
secretion of CRH into the hypophysial portal circulation. Following stress, CRH
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mRNA increases in the medial parvocellular region of the PVN (Lightman and
Young, 1988; Lightman and Young, 1989). This most likely represents an increase
in the synthesis of CRH to replenish CRH stores released during stress. Presumably,

CRH is synthesized in PVN neurons until the releasable pools of CRH are restored to
pre-stress levels. In the castrated male rat, the size of the releasable pools of median
eminence CRH may be greater than in the intact male rat. In the final study of this
dissertation, the CORT and ACTH responses to stress were enhanced in the castrated
male on the fourth day of exposure to a stressor. Thus, it appears that the larger pool
of CRH in the castrated male is rapidly regenerated after a stressor. Therefore, if
changes in CRH gene expression are responsible for androgen's effect on
hypothalamic content of this peptide, this may be best observed after a stressor.
Androgen regulation of CRH neurons of the PVN is indirect. Androgen
receptor immunoreactivity was not observed within CRH expressing neurons of the
PVN. Circulating androgens may act on other CNS neurons to modify levels of
glucocorticoid or mineralocorticoid receptors and/or some neuromodulator which
ultimately alters the pools of CRH stored in median eminence terminals. The PVN is
a highly integrated and regulated cell group (for rev. see Swanson and Sawchenko,
1983), and there are many possible target sites at which steroids could act to
ultimately regulate CRH cells within the PVN. Several CNS sites have androgen
responsive neurons and project to the PVN. These sites include limbic regions such
as the bed nucleus of the stria terminalis (BNST) and the septum as well as brainstem
sites such as the midbrain raphe (Sar and Stumpf, 1977; Swanson, 1987).
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It is also possible that androgen responsive cells such as those in the

hippocampus modify hypothalamic CRH content via a multisynaptic pathway.
Interestingly, it has been reported that implantation of the synthetic glucocorticoid,
dexamethasone, into the hippocampus results in a slight decrease in the
adrenalectomy-induced effects on CRH immunoreactivity (Kovacs et al., 1986) while
no effect was seen on CRH mRNA (Kovacs and Mezey, 1987). Androgens may act
on the hippocampus to similarly influence hypothalamic CRH.
This putative effect of androgens on the hippocampus may contribute to the
enhanced activity of the HPA axis observed in the aged male rat. Extensive research
has demonstrated an effect of adrenal steroids on the destruction of hippocampal
neurons. ACTH or cortisone treatment of guinea pigs causes necrosis of pyramidal
neurons of the hippocampus (Aus der Muhlen and Ockenfels, 1969). Furthermore, in
the rat, aging results in the loss of some pyramidal neurons in the hippocampus
(Landfield, 1987). This loss can be reduced by adrenalectomy in mid-life (Landfield,
1987). Daily injections of corticosterone to young adult male rats mimicks the
neuronal loss observed during aging (Sapolsky et al., 1985). Excitatory amino acids
play an important role in this pyramidal cell loss (for rev. see Sapolsky, 1990).
Corticosterone exacerbates kainic acid-induced hippocampal damage (Sapolsky, 1986),
and glucocorticoids enhance the excitatory amino acid-induced loss of hippocampal
neurons in culture (Sapolsky et al., 1988). Moreover, extensive research has
provided evidence that the activity of the HPA axis is enhanced in the aging male rat
(for rev. see McEwen, 1992). Since there is significant evidence implicating .the
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bippocampus in the feedback inhibition of the HPA axis (for rev. see Jacobsen and
Sapolsky, 1991), the "glucocorticoid cascade hypothesis" of stress and aging was
generated in an attempt to formulate a causal relationship between the activity of the
HPA axis and the deleterious actions of glucocorticoids on the viability of neurons in

the hippocampus (for rev. see Sapolsky et al., 1986). It is possible that circulating
androgens contribute to the enhanced activity of the HPA axis observed in the aged
male rat. Studies in this dissertation and elsewhere (Critchlow et al., 1963; Gaskin
and Kitay, 1971; Banda et al., 1994) demonstrate that circulating androgens inhibit
HPA activity. Moreover, circulating androgens are known to decline in the aging

male rat (Kaler and Neaves, 1981). Interestingly, a recent report suggests that
circulating androgens protect hippocampal neurons from the N-methyl-D-aspartic acid(NMDA-) induced loss of membrane activity (Pouliot et al., 1993). This suggests
that circulating androgens may influence glutamatergic responses in hippocampal
pyramidal neurons to ultimately inhibit HPA activity. Thus, loss of cirulating
androgens may contribute to the enhanced activity of the HPA axis in the aging male
rat.

The Stress Response
In the final study of this dissertation (Chapter VI), several indices of the stress
response were evaluated in terms of possible androgen regulation. The various
components of the stress response are controlled by overlapping but different neuronal
pathways. For example, serotonin stimulates the secretion of CRH and putative
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prolactin- and renin-releasing factors (for rev. see Van de Kar, 1991). CRH secretion
is also stimulated by catecholamines and acetylcholine and inhibited by GABA and
opioid peptides (for rev. see Owens and Nemeroff, 1991). Furthermore, prolactin
release from the pituitary is tonically inhibited by dopamine (Ben-Jonathon, 1985).
Thus, the evaluation of several indices of stress may make it possible to gain insight
into where and how androgens may be acting to alter the stress response. The
absence of circulating gonadal androgens enhanced the ACTH and corticosterone
responses and attenuated the prolactin response to conditioned stress. The nonaromatizable androgen, DHT, increased the expression of stress-like behaviors. The
renin response to conditioned stress was not altered by circulating androgens.
In addition to the data from this study, hypotheses can be formed based on the
results of a study localizing androgen receptor immunoreactivity to peptidergic
neurons of the forebrain (Chapter V). In this experiment, androgen receptor
immunoreactivity was observed within galanin expressing cells of the ventrolateral
BNST. Testosterone regulation of galanin gene expression in the BNST has been
reported (Miller et al., 1993a). Cells in the ventrolateral BNST have been
demonstrated to project to the PVN (Sawchenko and Swanson, 1983). Ibotenic acid
lesion of the ventrolateral BNST attenuates the stress-induced increases in ACTH,
corticosterone, and prolactin without influencing the renin response to stress (Gray et

al., 1993). Interestingly, infusion of galanin into the PVN attenuates the stressinduced increase in plasma ACTH (Hooi et al., 1990), and galanin has been shown to
have a regulatory role in the secretion of prolactin (Koshiyama et al., 1987;
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Nordstrom et al., 1987; Ottlecz et al., 1988).
Galanin may alter an organisms response to stress through its actions on other
central neurotransmitter systems. In the central nervous system, galanin is known to
influence noradrenergic, serotonergic, and cholinergic systems (for rev. see Bartfai et

al., 1993). For example, studies in rat indicate that intracerebroventricular injections
of galanin potently stimulate the serotonin metabolism in the hippocampus and median
eminence (Sundstrom and Melander, 1988). Moreover, galanin appears to increase
the affinity of 5-HT1A receptors for serotonin (Fuxe et al., 1988). Substantial
evidence suggests that 5-HT1A receptors are involved in the serotonin-induced
secretion of ACTH but not in the serotonin-induced secretion of renin (for rev. see
Van de Kar, 1991). Furthermore, 5-HT1A receptors may play a role in the expression
of CRH-induced behavior (Lazosky and Britton, 1991), a putative analogue of stressinduced behavior (Koob et al., 1993).
Taken together, these studies suggest the possibility that androgens may alter
the response to stressful stimuli through its regulation of galaninergic and ultimately
serotonergic systems. Clearly, androgens could be acting on any number of
neuroanatomical and neurochemical systems to affect changes in the response to
stress. However, future studies evaluating androgen regulation of galaninergic and
serotonergic transmitter systems may be useful in determining the mechanism(s) by
which androgens alter the physiological and behavioral responses to stress.
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Implications and Conclusions
The integrity of the HPA axis is essential for a normal response to threatening
stimuli. Abnormal funtion of the HPA axis has been associated with psychological
disorders such as depression (Kalin and Dawson, 1986) and panic disorder (Henry,
1990). For example, depression is often brought on by stressful episodes (Paykel,
1979) and has been associated with excessive secretion of HPA hormones (Kalin and
Dawson, 1986).
In humans, depression and panic disorder occur much more often in females
than in males (Weissman and Klerman, 1977; Katschnig and Amering, 1990).
Correspondingly, experimental data in rats reveal a sex difference in the
corticosterone response to stress (Kitay, 1961). Several studies have indicated that
estrogen acts to enhance HPA activity (Kitay, 1963; Viau and Meaney, 1991a;
Burgess and Handa, 1992) while androgens may inhibit activity of the HPA axis
(Critchlow and Kitay, 1963; Gaskin and Kitay, 1971; Handa et al., 1994; Bingaman

et al., 1994). Thus, while estrogen may play an important role in predisposing a
female to such disorders, androgens may protect a male from dysfunction of the stress
response.
These phenomena are also important in light of the various conditions
involving altered gonadal function as well as behaviors which have been linked to
HPA dysfunction. For example, Klinefelter's Syndrome, a genetic disorder present in
1 in 1000 male births (Baker et al., 1976), is marked by unusually low testosterone
levels throughout life (Schwartz and Root, 1991). Klinefelter males often exhibit
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extreme depression (Nielsen et al., 1988; Schwartz and Root, 1991). Also, in the
elderly, gonadal hormones are known to diminish (Kaler and Neaves, 1981; Baker et

al., 1976) while the HPA response to stress is exaggerated (Sapolsky et al., 1984b).
Moreover, a higher incidence of depression is seen among the elderly (Sorensen and
Stromgren, 1961). One might contend that other factors (death of a spouse, low
income, reduced mobility, etc.) may be the cause of depression in the elderly.
However, it is possible that the stress associated with these factors, and the
inappropriate biological response to that stress, could be involved in the onset of
depression.
It is important to note that most studies investigating the effect of gonadal

hormones on the stress response have sampled only one or two parameters of the
stress response. In the final study of this dissertation, the effects of circulating
androgens on neuroendocrine, autonomic, and behavioral indices of stress were
evaluated in order to determine whether androgens selectively or globally modulate
the expression of various parameters of the stress response. Interestingly, removal of
circulating gonadal androgens enhanced the ACTH and corticosterone responses and
attenuated the plasma prolactin response to conditioned stress. Also, while androgens
potentiated the behavioral response to stress, the absence of gonadal androgens did not
influence plasma renin activity and concentration or defecation following conditioned
stress. Circulating androgens differentially modulate the neural systems responsible
for expression of various components of the stress response. Thus, examination of
only one aspect of the stress response such as ACTH and/or corticosterone may be
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misleading. Evaluating other neuroendocrine as well as autonomic and behavioral
reactions to stress may be necessary in order to determine how an organism is
reacting to environmental perturbation. It may be important for researchers to sample
several indices of stress in order to gain a more accurate "profile" of the stress
response.
It should also be emphasized that gonadal steroids do not cause a female to be

"more stressed" or "less stressed" than a male. Gonadal steroids cause males and
females to be stressed differently from each other. That is, males may exhibit more
stress-like behaviors and less of an HPA response to stress. Furthermore, other
hormonal and autonomic responses to stress may be more or less in males compared
to females. Thus, females may be more susceptible to depression, not because they
are "more stressed" than males beut rather because they respond to stressful stimuli
differentally than males.

The studies in this dissertation have demonstrated that circulating gonadal
androgens play an important role in the regulation of an organism's response to
environmental perturbation. Circulating androgens suppress the HPA axis via central
mechanisms. In contrast, androgens have a facilitatory effect on prolactin secretion.
These effects are quite pronounced when the animal is challenged with a stressor. In
the absence of circulating androgens the machinery with which an organism copes
with its environment is weakened, and exposure to either physical or psychological
stress brings out that weakness. In this manner, an inadequate gonadal steroid
secretion can lead to pathological conditions like depression. Future studies of the
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site(s) and mechanism(s) of androgen action will not only provide an understanding of
gonadal influences on the physiological adaptation to stress, but may be important in
providing an understanding of the biological basis underlying behaviors such as
depression.
This dissertation also points out the importance of testosterone as a regulator
of evolution. Survival of the organism and survival of the species are of utmost
importance. Obviously, testosterone acts to contributes to the survival of a species by
directly regulating reproduction. However, circulating testosterone may indirectly
enhance both survival of the species and survival of the organism through its
regulation of the stress response. Since products of the HPA axis inhibit reproductive
function (Plas-Rose and Aron, 1981; Sirinathsinghji et al., 1983; Rivier and Vale,
1984; Rivier and Vale 1985b; Rivier et al., 1986; Armstrong, 1986; Sirinathsinghji et

al., 1986; Kamel and Kubajak, 1987), circulating testosterone indirectly enhances
reproduction by inhibiting HPA activity. In this manner, circulating androgens
indirectly enhance survival of the species. Additionally circulating testosterone
potentiates the prolactin response to stress. Since prolactin is thought to enhance
immune function (Spangelo et al., 1987; Cross et al., 1989; Dardenne et al., 1989;
Mukherjee et al., 1990) circulating testosterone may indirectly enhance the survival of
the organism through it's regulation of the prolactin response to stressful stimuli. It
seems appropiate that testosterone would play this major role in the evolution process.
An organism contributes to the evolution of its species during and prior to its

reproductive stage. What better mediator of the evolutionary process than

144
testosterone, a hormone that is only produced in great amounts during a male's
reproductive stage. Clearly, circulating androgens represent a major mediator of
evolution.
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